<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2015//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_150101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19496084</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>08</Month>
            <Day>17</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>10</Month>
            <Day>22</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1613-4133</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>53</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Molecular nutrition &amp; food research</Title>
                <ISOAbbreviation>Mol Nutr Food Res</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Dietary quercetin alleviates diabetic symptoms and reduces streptozotocin-induced disturbance of hepatic gene expression in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>859-68</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/mnfr.200800310</ELocationID>
            <Abstract>
                <AbstractText>Quercetin is a food component that may ameliorate the diabetic symptoms. We examined hepatic gene expression of BALB/c mice with streptozotocin (STZ)-induced diabetes to elucidate the mechanism of the protective effect of dietary quercetin on diabetes-associated liver injury. We fed normal and STZ-induced diabetic mice with diets containing quercetin for 2 wk and compared the patterns of hepatic gene expression in these groups of mice using a DNA microarray. Diets containing 0.1 or 0.5% quercetin lowered the STZ-induced increase in blood glucose levels and improved plasma insulin levels. A cluster analysis of the hepatic gene expressions showed that 0.5% quercetin diet suppressed STZ-induced alteration of gene expression. Gene set enrichment analysis (GSEA) and quantitative RT-PCR analysis showed that the quercetin diets had greatest suppressive effect on the STZ-induced elevation of expression of cyclin-dependent kinase inhibitor p21(WAF1/Cip1) (Cdkn1a). Quercetin also suppressed STZ-induced expression of Cdkn1a in the pancreas. Dietary quercetin might improve liver and pancreas functions by enabling the recovery of cell proliferation through the inhibition of Cdkn1a expression. Unexpectedly, in healthy control mice the 0.5 and 1% quercetin diets reduced the expression of ubiquitin C (Ubc), which has heat-shock element (HSE) in the promoter region, in the liver.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kobori</LastName>
                    <ForeName>Msauko</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>National Food Research Institute, National Agriculture and Food Research Organisation, Tsukuba, Ibaraki, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Masumoto</LastName>
                    <ForeName>Saeko</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Akimoto</LastName>
                    <ForeName>Yukari</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Takahashi</LastName>
                    <ForeName>Yumiko</ForeName>
                    <Initials>Y</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Mol Nutr Food Res</MedlineTA>
            <NlmUniqueID>101231818</NlmUniqueID>
            <ISSNLinking>1613-4125</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C493957">Cdkn1a protein, mouse</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D050759">Cyclin-Dependent Kinase Inhibitor p21</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007328">Insulin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D025822">Ubiquitin C</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>5W494URQ81</RegistryNumber>
                <NameOfSubstance UI="D013311">Streptozocin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9IKM0I5T1E</RegistryNumber>
                <NameOfSubstance UI="D011794">Quercetin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001786">Blood Glucose</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D050759">Cyclin-Dependent Kinase Inhibitor p21</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003921">Diabetes Mellitus, Experimental</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020869">Gene Expression Profiling</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007328">Insulin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008099">Liver</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018384">Oxidative Stress</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010179">Pancreas</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011794">Quercetin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013311">Streptozocin</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D025822">Ubiquitin C</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>6</Month>
                <Day>5</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>6</Month>
                <Day>6</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>10</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mnfr.200800310</ArticleId>
            <ArticleId IdType="pubmed">19496084</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">16292651</PMID>
        <DateCreated>
            <Year>2006</Year>
            <Month>01</Month>
            <Day>09</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2006</Year>
            <Month>05</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0179-0358</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>22</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2006</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Pediatric surgery international</Title>
                <ISOAbbreviation>Pediatr. Surg. Int.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Altered renin-angiotensin system gene expression causes renal hypoplasia in the rats with nitrofen-induced diaphragmatic hernia.</ArticleTitle>
            <Pagination>
                <MedlinePgn>57-60</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The association between renal hypoplasia and pulmonary hypoplasia in congenital diaphragmatic hernia (CDH) has become recently appreciated. However, the underlying mechanisms responsible for this association are still unknown. Renin-angiotensin system (RAS) plays an important role in renal and somatic growth, angiogenesis and reproduction. We hypothesized that abnormal expression of RAS components may be responsible for renal hypoplasia in CDH. We therefore designed this study to examine the gene expression of main components of RAS in the kidney of nitrofen-induced CDH in the rat. Pregnant rats were exposed to either olive oil or 100 mg of nitrofen on day 9.5 of gestation. Foetuses were recovered at term and divided into three groups: control (n=8), nitrofen without CDH (n=8) and CDH (n=8). Reverse transcription polymerase chain reaction was performed to evaluate the relative amount of angiotensinogen (AGT), angiotensin II type 1 receptor with 1a and 1b subtypes (AT(1a)R and AT(1b)R), angiotensin II type 2 receptor (AT(2)R), angiotensin-converting enzyme (ACE) and renin expression in the kidney. AT(1a)R, AT(1b)R, AT(2)R, AGT and renin levels were significantly decreased in the kidney of CDH rats compared with controls. We did not find a significant difference in ACE between CDH animals and controls. Our data show that the downregulation of RAS may play an important role in the pathogenesis of renal hypoplasia in the nitrofen-induced CDH.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Chertin</LastName>
                    <ForeName>Boris</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Children's Research Centre, Our Lady's Hospital for Sick Children, Crumlin, Dublin 12, Ireland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nakazawa</LastName>
                    <ForeName>Nana</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Montedonico</LastName>
                    <ForeName>Sandra</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shima</LastName>
                    <ForeName>Hideki</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Puri</LastName>
                    <ForeName>Prem</ForeName>
                    <Initials>P</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D023362">Evaluation Studies</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Pediatr Surg Int</MedlineTA>
            <NlmUniqueID>8609169</NlmUniqueID>
            <ISSNLinking>0179-0358</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010647">Phenyl Ethers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>1836-75-5</RegistryNumber>
                <NameOfSubstance UI="C007350">nitrofen</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000015">Abnormalities, Multiple</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000196">embryology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015536">Down-Regulation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D018507">Gene Expression Regulation, Developmental</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006548">Hernia, Diaphragmatic</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000196">embryology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D065630">Hernias, Diaphragmatic, Congenital</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007668">Kidney</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000002">abnormalities</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000196">embryology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010647">Phenyl Ethers</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011247">Pregnancy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017207">Rats, Sprague-Dawley</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012084">Renin-Angiotensin System</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2005</Year>
                <Month>11</Month>
                <Day>18</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2006</Year>
                <Month>5</Month>
                <Day>26</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2005</Year>
                <Month>11</Month>
                <Day>18</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00383-005-1582-7</ArticleId>
            <ArticleId IdType="pubmed">16292651</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">3852897</PMID>
        <DateCreated>
            <Year>1986</Year>
            <Month>01</Month>
            <Day>28</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1986</Year>
            <Month>01</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0368-2781</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>38</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>1985</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Japanese journal of antibiotics</Title>
                <ISOAbbreviation>Jpn J Antibiot</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Bacteriological efficacy of nafcillin and vancomycin alone or combined with rifampicin or amikacin in experimental meningitis due to methicillin-susceptible or -resistant Staphylococcus aureus.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2155-62</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The pharmacokinetics and bacteriological efficacy of nafcillin (NFPC), vancomycin (VCM), amikacin (AMK) and rifampicin (RFP) alone and in VCM combinations were evaluated in the experimental rabbit meningitis caused by methicillin-susceptible Staphylococcus aureus (MSSA) or methicillin-resistant Staphylococcus aureus (MRSA). The mean concentrations of NFPC, VCM, AMK and RFP in cerebrospinal fluid (CSF) with MSSA meningitis exceeded the minimal bactericidal concentrations of MSSA during 8 hours therapy period. The mean CSF penetration rates of the 4 drugs during therapy were from 1% to 26% which are comparable to those observed in humans with meningitis. The median CSF bactericidal titers of RFP, VCM plus RFP, AMK, VCM plus AMK regimens were larger than 1:8 during therapy of MSSA meningitis study. In experimental MRSA meningitis, RFP and VCM plus RFP achieved titers greater than 1: 16 during therapy and at 24 hours. No statistically significant reduction in the CSF bacterial colony count was obtained with any of the antibiotic regimens in MSSA meningitis. By contrast, in 8 hours MRSA meningitis model, significant reductions in the number of MRSA were observed in animals treated for 8 hours with VCM plus RFP (P less than 0.01), RFP (P less than 0.05), and NFPC plus RFP (P less than 0.01).</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sato</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lin</LastName>
                    <ForeName>T Y</ForeName>
                    <Initials>TY</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Weintrub</LastName>
                    <ForeName>L</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Olsen</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McCracken</LastName>
                    <ForeName>G H</ForeName>
                    <Initials>GH</Initials>
                    <Suffix>Jr</Suffix>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>JAPAN</Country>
            <MedlineTA>Jpn J Antibiot</MedlineTA>
            <NlmUniqueID>0154402</NlmUniqueID>
            <ISSNLinking>0368-2781</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>4CNZ27M7RV</RegistryNumber>
                <NameOfSubstance UI="D009254">Nafcillin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>59-01-8</RegistryNumber>
                <NameOfSubstance UI="D007612">Kanamycin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>6Q205EH1VU</RegistryNumber>
                <NameOfSubstance UI="D014640">Vancomycin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>84319SGC3C</RegistryNumber>
                <NameOfSubstance UI="D000583">Amikacin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>Q91FH1328A</RegistryNumber>
                <NameOfSubstance UI="D008712">Methicillin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>VJT6J7R4TR</RegistryNumber>
                <NameOfSubstance UI="D012293">Rifampin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000583">Amikacin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007612">Kanamycin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007700">Kinetics</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008581">Meningitis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008712">Methicillin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009254">Nafcillin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010403">Penicillin Resistance</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011817">Rabbits</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012293">Rifampin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013203">Staphylococcal Infections</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013211">Staphylococcus aureus</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014640">Vancomycin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1985</Year>
                <Month>8</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2001</Year>
                <Month>3</Month>
                <Day>28</Day>
                <Hour>10</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1985</Year>
                <Month>8</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3852897</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">7057304</PMID>
        <DateCreated>
            <Year>1982</Year>
            <Month>04</Month>
            <Day>22</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1982</Year>
            <Month>04</Month>
            <Day>22</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0022-3476</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>100</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>1982</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of pediatrics</Title>
                <ISOAbbreviation>J. Pediatr.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Dilantin toxicity in a preterm infant: persistent bradycardia and lethargy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>146-9</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wiriyathian</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kaojarern</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rosenfeld</LastName>
                    <ForeName>C R</ForeName>
                    <Initials>CR</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>J Pediatr</MedlineTA>
            <NlmUniqueID>0375410</NlmUniqueID>
            <ISSNLinking>0022-3476</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>6158TKW0C5</RegistryNumber>
                <NameOfSubstance UI="D010672">Phenytoin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>YQE403BP4D</RegistryNumber>
                <NameOfSubstance UI="D010634">Phenobarbital</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001919">Bradycardia</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006321">Heart</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007231">Infant, Newborn</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007235">Infant, Premature, Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010634">Phenobarbital</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010672">Phenytoin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012640">Seizures</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012894">Sleep Stages</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1982</Year>
                <Month>1</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1982</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1982</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">7057304</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">8398704</PMID>
        <DateCreated>
            <Year>1993</Year>
            <Month>11</Month>
            <Day>15</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1993</Year>
            <Month>11</Month>
            <Day>15</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0007-0920</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>68</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>1993</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>British journal of cancer</Title>
                <ISOAbbreviation>Br. J. Cancer</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Phase I/pharmacokinetic/biochemical study of the nitroimadazole hypoxic cell sensitiser SR2508 (etanidazole) in combination with cyclophosphamide.</ArticleTitle>
            <Pagination>
                <MedlinePgn>756-66</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>SR2508 sensitises certain hypoxic tumor cells in vitro and in vivo to the cytotoxic action of radiation and alkylating agents. The mechanism of sensitisation may derive in part from depletion of glutathione (GSH) and possibly inhibition of GSH-dependent enzymes in target cells. We treated 46 evaluable patients with cyclophosphamide 750-1000 mg m-2 followed by SR2508 at eight dose levels ranging from 2.5 to 15.0 g m-2. Each patient received SR2508 as a single agent initially, followed a week later by the combination of cyclophosphamide and SR2508. Initially, myelosuppression was the major toxicity; potentiation of cyclophosphamide-induced leukopenia by SR2508 required a dose reduction of cyclophosphamide to 750 mg m-2 at SR2508 doses above 7.2 g m-2. At doses above 9.4 g m-2 an acute syndrome of muscle pains and painful paresthesias of the extremities lasting 12-24 h was observed to occur with increasing severity. This side-effect was intolerable in two of three patients treated at 15.0 g m-2. The only other reproducible side-effect was nausea and vomiting which was controllable with antiemetics. Plasma and urine SR2508 concentrations were measured by HPLC in 45 patients. Plasma elimination curves fit a 2-compartment model. The mean terminal half-life at each dose level ranged from 5.1-5.8 h. The mean area under the plasma concentration-time curve was linearly related to dose, and mean total body clearance ranged from 46.6-94.0 ml-1 min-1 m-2; renal clearance accounted for 65.7-79.3%. Pretreatment with cyclophosphamide did not influence the kinetics of SR2508 in individual patients. Examination of the glutathione content of peripheral mononuclear cells and tumour samples showed that depletion to below 50% of control occurred in the majority of patients. GSH transferase inhibition occurred with a similar time-course, but to a lesser extent. These data suggest that the further evaluation of this regimen should be conducted with SR2508 administration preceding that of cyclophosphamide and that its evaluation in cyclophosphamide-sensitive tumours is warranted.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>O'Dwyer</LastName>
                    <ForeName>P J</ForeName>
                    <Initials>PJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>LaCreta</LastName>
                    <ForeName>F P</ForeName>
                    <Initials>FP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Walczak</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cox</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Litwin</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hoffman</LastName>
                    <ForeName>J P</ForeName>
                    <Initials>JP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zimny</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Comis</LastName>
                    <ForeName>R L</ForeName>
                    <Initials>RL</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>CA49820-01</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016430">Clinical Trial</PublicationType>
                <PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>ENGLAND</Country>
            <MedlineTA>Br J Cancer</MedlineTA>
            <NlmUniqueID>0370635</NlmUniqueID>
            <ISSNLinking>0007-0920</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>30DKA3Q1HL</RegistryNumber>
                <NameOfSubstance UI="D017341">Etanidazole</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>8N3DW7272P</RegistryNumber>
                <NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.5.1.18</RegistryNumber>
                <NameOfSubstance UI="D005982">Glutathione Transferase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>GAN16C9B8O</RegistryNumber>
                <NameOfSubstance UI="D005978">Glutathione</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Radiat Res. 1984 Jun;98(3):506-18</RefSource>
                <PMID Version="1">6233628</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 1990 Jul;19(1):197-202</RefSource>
                <PMID Version="1">2143178</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 1984 Sep;10(9):1749-53</RefSource>
                <PMID Version="1">6237086</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Treat Rep. 1985 Jun;69(6):677-82</RefSource>
                <PMID Version="1">4016771</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Pharmacol. 1986 Jan 1;35(1):111-5</RefSource>
                <PMID Version="1">3940521</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Psychiatr Res. 1975 Nov;12(3):189-98</RefSource>
                <PMID Version="1">1202204</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Radiat Res. 1980 Apr;82(1):171-90</RefSource>
                <PMID Version="1">7367588</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Anal Biochem. 1980 Jul 15;106(1):207-12</RefSource>
                <PMID Version="1">7416462</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer. 1981 Jan 1;47(1):207-14</RefSource>
                <PMID Version="1">7459811</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 1980 Nov;40(11):4165-72</RefSource>
                <PMID Version="1">7471058</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Cancer. 1981 Aug;44(2):208-18</RefSource>
                <PMID Version="1">7272187</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 1981 Jun;7(6):695-703</RefSource>
                <PMID Version="1">6457018</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Methods Enzymol. 1981;77:398-405</RefSource>
                <PMID Version="1">7329316</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 1983 Feb;9(2):227-32</RefSource>
                <PMID Version="1">6339448</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 1983 Jul;43(7):3175-81</RefSource>
                <PMID Version="1">6850627</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Cancer. 1983 Sep;48(3):375-83</RefSource>
                <PMID Version="1">6615699</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 1984 Jan;44(1):91-6</RefSource>
                <PMID Version="1">6690065</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Cancer. 1984 Jan;49(1):33-42</RefSource>
                <PMID Version="1">6229264</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Pharmacol. 1984 Apr 15;33(8):1379-81</RefSource>
                <PMID Version="1">6201179</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Pharmacol. 1986 Jan 1;35(1):71-6</RefSource>
                <PMID Version="1">2934067</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 1986 Jul;12(7):1105-8</RefSource>
                <PMID Version="1">3017904</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 1986 Jul;12(7):1223-6</RefSource>
                <PMID Version="1">2943714</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Pharmacol. 1986 Sep 15;35(18):3143-6</RefSource>
                <PMID Version="1">3753520</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 1986 Aug;12(8):1389-92</RefSource>
                <PMID Version="1">3759561</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 1987 Jan 1;47(1):319-22</RefSource>
                <PMID Version="1">3024818</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Cancer. 1987 Aug;56(2):103-9</RefSource>
                <PMID Version="1">3663461</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 1988 Apr 8;240(4849):177-84</RefSource>
                <PMID Version="1">2451290</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 1988 Apr;6(4):709-33</RefSource>
                <PMID Version="1">3282035</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 1991 Feb 15;51(4):1099-104</RefSource>
                <PMID Version="1">1825475</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Treat Rev. 1990 Dec;17 Suppl A:45-50</RefSource>
                <PMID Version="1">2092870</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Radiat Oncol Biol Phys. 1984 Sep;10(9):1603-7</RefSource>
                <PMID Version="1">6480448</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Radiother Oncol. 1989 May;15(1):103-14</RefSource>
                <PMID Version="1">2748937</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Cancer. 1990 Jan;61(1):61-4</RefSource>
                <PMID Version="1">2297491</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Cancer. 1955 Dec;9(4):539-49</RefSource>
                <PMID Version="1">13304213</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003520">Cyclophosphamide</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004334">Drug Administration Schedule</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017341">Etanidazole</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005978">Glutathione</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005982">Glutathione Transferase</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007970">Leukopenia</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009422">Nervous System Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009503">Neutropenia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC1968592</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1993</Year>
                <Month>10</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1993</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1993</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8398704</ArticleId>
            <ArticleId IdType="pmc">PMC1968592</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">15699457</PMID>
        <DateCreated>
            <Year>2005</Year>
            <Month>03</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2005</Year>
            <Month>10</Month>
            <Day>27</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1524-4563</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>45</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2005</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Hypertension</Title>
                <ISOAbbreviation>Hypertension</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension.</ArticleTitle>
            <Pagination>
                <MedlinePgn>759-65</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The soluble epoxide hydrolase (sEH) metabolizes vasodilatory epoxyeicosatrienoic acids (EETs) to their di-hydroxy derivatives. We hypothesized that the metabolism of EETs by the sEH contributes to angiotensin II-induced hypertension and tested the effects of a water-soluble sEH inhibitor, 12-(3-adamantan-1-yl-ureido) dodecanoic acid (AUDA) on blood pressure. AUDA (130 microg/mL in drinking water) did not affect blood pressure in normotensive animals but markedly lowered it in mice with angiotensin II-induced hypertension (1 mg/kg per day). The effect of AUDA was accompanied by an increase in urinary salt and water excretion. Intravenous application of AUDA (8 mg/kg) acutely lowered blood pressure and heart rate in animals with angiotensin II-induced hypertension but failed to affect blood pressure in animals with phenylephrine-induced hypertension (29 mg/kg per day). AUDA (0.1 micromol/L) selectively lowered vascular resistance in an isolated perfused kidney preparation from angiotensin II-pretreated mice but not from control mice. In the perfused hind limb and in isolated carotid arteries from angiotensin II-treated mice, AUDA was without effect. The omega-hydroxylase inhibitor N-methylsulfonyl-12,12-dibromododec-11-enamide, which attenuates formation of the potent vasoconstrictor 20-hydroxyeicosatetraenoic acid, decreased tone in carotid arteries from angiotensin II-treated but not from control mice. These data demonstrate that the decrease in blood pressure observed after sEH inhibition in angiotensin II-induced hypertension can be attributed to an initial reduction in heart rate followed by pressure diuresis resulting from increased perfusion of the kidney. Direct vasodilatation of resistance arteries in skeletal muscles does not appear to contribute to the antihypertensive effects of sEH inhibition in mice.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Jung</LastName>
                    <ForeName>Oliver</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institut fr Kardiovaskulre Physiologie and ZAFES, Johann Wolfgang Goethe-Universitt, Frankfurt am Main, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brandes</LastName>
                    <ForeName>Ralf P</ForeName>
                    <Initials>RP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>In-Hae</ForeName>
                    <Initials>IH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schweda</LastName>
                    <ForeName>Frank</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schmidt</LastName>
                    <ForeName>Ronald</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hammock</LastName>
                    <ForeName>Bruce D</ForeName>
                    <Initials>BD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Busse</LastName>
                    <ForeName>Rudi</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fleming</LastName>
                    <ForeName>Ingrid</ForeName>
                    <Initials>I</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>ES02710</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>HL59699-06A1</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P42 ES04699</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2005</Year>
                <Month>02</Month>
                <Day>07</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Hypertension</MedlineTA>
            <NlmUniqueID>7906255</NlmUniqueID>
            <ISSNLinking>0194-911X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C504897">12-(3-adamantan-1-ylureido)dodecanoic acid</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000577">Amides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006893">Hydroxyeicosatetraenoic Acids</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007850">Lauric Acids</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013450">Sulfones</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014662">Vasoconstrictor Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>11128-99-7</RegistryNumber>
                <NameOfSubstance UI="D000804">Angiotensin II</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>79551-86-3</RegistryNumber>
                <NameOfSubstance UI="C055987">20-hydroxy-5,8,11,14-eicosatetraenoic acid</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>B7RXR6O461</RegistryNumber>
                <NameOfSubstance UI="C117975">DDMS</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.3.2.-</RegistryNumber>
                <NameOfSubstance UI="D004851">Epoxide Hydrolases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>PJY633525U</RegistryNumber>
                <NameOfSubstance UI="D000218">Adamantane</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000218">Adamantane</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000031">analogs &amp; derivatives</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000577">Amides</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D000804">Angiotensin II</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000959">Antihypertensive Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001794">Blood Pressure</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004231">Diuresis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004851">Epoxide Hydrolases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006893">Hydroxyeicosatetraenoic Acids</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006973">Hypertension</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D066298">In Vitro Techniques</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007850">Lauric Acids</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008815">Mice, Inbred Strains</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009318">Natriuresis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012079">Renal Circulation</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012995">Solubility</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013450">Sulfones</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D014662">Vasoconstrictor Agents</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014664">Vasodilation</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2005</Year>
                <Month>2</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2005</Year>
                <Month>2</Month>
                <Day>9</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2005</Year>
                <Month>10</Month>
                <Day>28</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2005</Year>
                <Month>2</Month>
                <Day>9</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">01.HYP.0000153792.29478.1d</ArticleId>
            <ArticleId IdType="doi">10.1161/01.HYP.0000153792.29478.1d</ArticleId>
            <ArticleId IdType="pubmed">15699457</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">1775410</PMID>
        <DateCreated>
            <Year>1992</Year>
            <Month>03</Month>
            <Day>03</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1992</Year>
            <Month>03</Month>
            <Day>03</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0032-5473</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>67</Volume>
                    <Issue>793</Issue>
                    <PubDate>
                        <Year>1991</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Postgraduate medical journal</Title>
                <ISOAbbreviation>Postgrad Med J</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Polymyositis complicating D-penicillamine treatment.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1018-20</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Although there is good evidence that D-penicillamine can induce polymyositis, the exact pathogenic mechanism remains unclear. We report two patients with psoriatic arthritis and primary biliary cirrhosis respectively, who developed polymyositis while receiving D-penicillamine treatment for their primary diseases. Whether D-penicillamine treatment was the sole cause of polymyositis or acted as a trigger for the development of a secondary autoimmune disease is discussed.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Aydintug</LastName>
                    <ForeName>A O</ForeName>
                    <Initials>AO</Initials>
                    <AffiliationInfo>
                        <Affiliation>Lupus Arthritis Research Unit, Rayne Institute, St Thomas' Hospital, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cervera</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>D'Cruz</LastName>
                    <ForeName>D</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ramrez</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Asherson</LastName>
                    <ForeName>R A</ForeName>
                    <Initials>RA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Khamashta</LastName>
                    <ForeName>M A</ForeName>
                    <Initials>MA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hughes</LastName>
                    <ForeName>G R</ForeName>
                    <Initials>GR</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>ENGLAND</Country>
            <MedlineTA>Postgrad Med J</MedlineTA>
            <NlmUniqueID>0234135</NlmUniqueID>
            <ISSNLinking>0032-5473</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>GNN1DV99GX</RegistryNumber>
                <NameOfSubstance UI="D010396">Penicillamine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Rheum Dis. 1991 Mar;50(3):191-5</RefSource>
                <PMID Version="1">2015017</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br Med J. 1975 Mar 15;1(5958):600-2</RefSource>
                <PMID Version="1">1125624</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arthritis Rheum. 1986 Apr;29(4):560-4</RefSource>
                <PMID Version="1">3707633</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Rheum Dis. 1982 Dec;41(6):617-20</RefSource>
                <PMID Version="1">6216862</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Intern Med. 1983 Mar;98(3):327-30</RefSource>
                <PMID Version="1">6830075</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Rheumatol Suppl. 1981 Jan-Feb;7:56-61</RefSource>
                <PMID Version="1">6971938</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>South Med J. 1981 Oct;74(10):1286</RefSource>
                <PMID Version="1">7292078</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Agents Actions Suppl. 1979;(5):159-67</RefSource>
                <PMID Version="1">294133</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Scand J Rheumatol. 1978;7(2):113-7</RefSource>
                <PMID Version="1">705267</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Rev Rhum Mal Osteoartic. 1977 Jul-Sep;44(7-9):497-501</RefSource>
                <PMID Version="1">910108</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Rheum Dis. 1977 Feb;36(1):94-5</RefSource>
                <PMID Version="1">843119</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br Med J. 1976 Dec 11;2(6049):1423-4</RefSource>
                <PMID Version="1">1009359</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Intern Med. 1976 Nov;85(5):615-6</RefSource>
                <PMID Version="1">984614</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arch Neurol. 1972 Nov;27(5):456-7</RefSource>
                <PMID Version="1">4116745</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Med Interne (Paris). 1974 Jan;125(1):71-9</RefSource>
                <PMID Version="1">4136184</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet. 1971 Feb 6;1(7693):292</RefSource>
                <PMID Version="1">4100034</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 1975 Feb 20;292(8):403-7</RefSource>
                <PMID Version="1">1089199</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Intern Med. 1975 May;82(5):673-6</RefSource>
                <PMID Version="1">1094875</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Rheumatol. 1987 Oct;14(5):995-1001</RefSource>
                <PMID Version="1">3501473</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015535">Arthritis, Psoriatic</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008105">Liver Cirrhosis, Biliary</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009220">Myositis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010396">Penicillamine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC2399149</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1991</Year>
                <Month>11</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1991</Year>
                <Month>11</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1991</Year>
                <Month>11</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1775410</ArticleId>
            <ArticleId IdType="pmc">PMC2399149</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">21093581</PMID>
        <DateCreated>
            <Year>2011</Year>
            <Month>04</Month>
            <Day>12</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2011</Year>
            <Month>07</Month>
            <Day>26</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>09</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-1708</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>31</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2011</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Reproductive toxicology (Elmsford, N.Y.)</Title>
                <ISOAbbreviation>Reprod. Toxicol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Developmental dioxin exposure of either parent is associated with an increased risk of preterm birth in adult mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>351-8</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.reprotox.2010.11.003</ELocationID>
            <Abstract>
                <AbstractText>We have previously described diminished uterine progesterone response and increased uterine sensitivity to inflammation in adult female mice with a history of developmental exposure to TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin). Since parturition in mammals is an inflammatory process mediated in part by a decline in progesterone action, toxicant-mediated disruption of progesterone receptor (PR) expression at the maternal-fetal interface would likely impact the timing of birth. Therefore, in the current study, we examined pregnancy outcomes in adult female mice with a similar in utero exposure to TCDD. We also examined the impact of in utero TCDD exposure of male mice on pregnancy outcomes in unexposed females since the placenta, a largely paternally derived organ, plays a major role in the timing of normal parturition via inflammatory signaling. Our studies indicate that developmental exposure of either parent to TCDD is associated with preterm birth in a subsequent adult pregnancy due to altered PR expression and placental inflammation.</AbstractText>
                <CopyrightInformation>Copyright  2010 Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ding</LastName>
                    <ForeName>Tianbing</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Women's Reproductive Health Research Center, Department of Obstetrics and Gynecology, Vanderbilt University School of Medicine, Nashville, TN 37232, United States.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McConaha</LastName>
                    <ForeName>Melinda</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Boyd</LastName>
                    <ForeName>Kelli L</ForeName>
                    <Initials>KL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Osteen</LastName>
                    <ForeName>Kevin G</ForeName>
                    <Initials>KG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bruner-Tran</LastName>
                    <ForeName>Kaylon L</ForeName>
                    <Initials>KL</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>R01 ES014942</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 ES014942-01</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01ES14942</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R21 AT006245</GrantID>
                    <Acronym>AT</Acronym>
                    <Agency>NCCAM NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R21 AT006245-01</GrantID>
                    <Acronym>AT</Acronym>
                    <Agency>NCCAM NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R21 AT006245-02</GrantID>
                    <Acronym>AT</Acronym>
                    <Agency>NCCAM NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R21AT006245-01</GrantID>
                    <Acronym>AT</Acronym>
                    <Agency>NCCAM NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2010</Year>
                <Month>11</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Reprod Toxicol</MedlineTA>
            <NlmUniqueID>8803591</NlmUniqueID>
            <ISSNLinking>0890-6238</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011980">Receptors, Progesterone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013723">Teratogens</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>DO80M48B6O</RegistryNumber>
                <NameOfSubstance UI="D013749">Tetrachlorodibenzodioxin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Endocrinol. 2008 Jan;22(1):105-12</RefSource>
                <PMID Version="1">17872381</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Reprod Toxicol. 2011 Apr;31(3):344-50</RefSource>
                <PMID Version="1">20955784</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2008 Jul 3;359(1):61-73</RefSource>
                <PMID Version="1">18596274</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2008;3(10):e3320</RefSource>
                <PMID Version="1">18833324</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Pathol. 2008 Dec;61(12):1261-75</RefSource>
                <PMID Version="1">19074631</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Reprod Sci. 2009 Feb;16(2):206-15</RefSource>
                <PMID Version="1">19208789</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Placenta. 2009 Mar;30 Suppl A:S90-5</RefSource>
                <PMID Version="1">19010537</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Endocrinol. 2009 Jul;23(7):947-54</RefSource>
                <PMID Version="1">19282364</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Immunol Lett. 2009 Aug 15;125(2):151-5</RefSource>
                <PMID Version="1">19607861</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2009;4(8):e6572</RefSource>
                <PMID Version="1">19668329</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Public Health. 2009 Oct;99(10):1864-71</RefSource>
                <PMID Version="1">19696383</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2009 Oct;27(4):197-211</RefSource>
                <PMID Version="1">19953395</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Semin Reprod Med. 2010 Jan;28(1):59-68</RefSource>
                <PMID Version="1">20104429</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Health Perspect. 2004 Oct;112(14):1403-8</RefSource>
                <PMID Version="1">15471733</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Endocrinology. 1974 Nov;95(5):1486-90</RefSource>
                <PMID Version="1">4473330</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biol Reprod. 1977 Sep;17(2):224-7</RefSource>
                <PMID Version="1">889994</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 1977 Aug 18;268(5621):633-4</RefSource>
                <PMID Version="1">561314</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Occup Hyg. 1979;22(4):327-67</RefSource>
                <PMID Version="1">161954</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 1984 Sep 27-Oct 3;311(5984):374-6</RefSource>
                <PMID Version="1">6482961</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Teratology. 1992 Jun;45(6):611-27</RefSource>
                <PMID Version="1">1412054</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Immunol Today. 1993 Jul;14(7):353-6</RefSource>
                <PMID Version="1">8363725</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Epidemiology. 1998 Mar;9(2):161-7</RefSource>
                <PMID Version="1">9504284</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Reprod Update. 1998 Jul-Aug;4(4):389-405</RefSource>
                <PMID Version="1">9825854</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Hum Reprod. 1999 May;5(5):481-6</RefSource>
                <PMID Version="1">10338372</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann N Y Acad Sci. 2004 Dec;1034:36-49</RefSource>
                <PMID Version="1">15731298</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Fertil Steril. 2005 Mar;83(3):529-37</RefSource>
                <PMID Version="1">15749474</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biol Pharm Bull. 2005 May;28(5):886-92</RefSource>
                <PMID Version="1">15863899</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Fertil Steril. 2005 Jul;84(1):67-74</RefSource>
                <PMID Version="1">16009159</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Steroid Biochem Mol Biol. 2005 Dec;97(5):435-8</RefSource>
                <PMID Version="1">16198556</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Neurosci Res. 2006 Mar;83(4):567-74</RefSource>
                <PMID Version="1">16435393</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Placenta. 2006 Jun-Jul;27(6-7):568-75</RefSource>
                <PMID Version="1">16122789</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Semin Reprod Med. 2006 Jul;24(3):168-77</RefSource>
                <PMID Version="1">16804815</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Reprod Immunol. 2006 Dec;72(1-2):46-59</RefSource>
                <PMID Version="1">16600383</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gynecol Obstet Invest. 2007;63(2):71-97</RefSource>
                <PMID Version="1">17028437</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Obstet Gynecol. 2007 Apr;196(4):289-96</RefSource>
                <PMID Version="1">17403397</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Reprod Toxicol. 2007 Apr-May;23(3):297-307</RefSource>
                <PMID Version="1">17046196</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Reprod Toxicol. 2007 Apr-May;23(3):326-36</RefSource>
                <PMID Version="1">17056225</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Lett. 2007 Jul 18;252(2):184-94</RefSource>
                <PMID Version="1">17189671</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 2007 Aug 15;179(4):2501-8</RefSource>
                <PMID Version="1">17675512</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Chemosphere. 2000 May-Jun;40(9-11):1247-53</RefSource>
                <PMID Version="1">10739069</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>JAMA. 2000 Aug 16;284(7):843-9</RefSource>
                <PMID Version="1">10938173</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Hum Reprod. 2001 Feb;7(2):175-83</RefSource>
                <PMID Version="1">11160844</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Steroids. 2002 Jan;67(1):1-14</RefSource>
                <PMID Version="1">11728516</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Reprod Health Matters. 2001 Nov;9(18):156-64</RefSource>
                <PMID Version="1">11765392</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 2002 Jan 15;168(2):554-61</RefSource>
                <PMID Version="1">11777946</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Appl Pharmacol. 2002 Feb 1;178(3):161-71</RefSource>
                <PMID Version="1">11858732</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Immunology. 2002 Sep;107(1):145-51</RefSource>
                <PMID Version="1">12225373</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Appl Pharmacol. 2002 Dec 15;185(3):197-206</RefSource>
                <PMID Version="1">12498736</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Health Perspect. 2003 Jun;111(7):947-53</RefSource>
                <PMID Version="1">12782497</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Pathol. 2003 Nov;163(5):2103-11</RefSource>
                <PMID Version="1">14578208</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biochem Mol Toxicol. 2003;17(6):305-15</RefSource>
                <PMID Version="1">14708085</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cell Endocrinol. 2004 Feb 12;214(1-2):39-52</RefSource>
                <PMID Version="1">15062543</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>BJOG. 2007 Nov;114(11):1326-34</RefSource>
                <PMID Version="1">17903232</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Opin Pediatr. 2010 Apr;22(2):208-18</RefSource>
                <PMID Version="1">20216314</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Depress Anxiety. 2010 Apr;27(4):327-38</RefSource>
                <PMID Version="1">20376837</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Epidemiology. 2010 May;21(3):291-9</RefSource>
                <PMID Version="1">20386169</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Histol Histopathol. 2010 Jul;25(7):945-56</RefSource>
                <PMID Version="1">20503182</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Obstet Gynaecol Can. 2010 Jun;32(6):541-8</RefSource>
                <PMID Version="1">20569534</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biogerontology. 2010 Oct;11(5):523-5</RefSource>
                <PMID Version="1">20717725</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Reprod. 2008 Jun;23(6):1290-6</RefSource>
                <PMID Version="1">18256111</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D044127">Epigenesis, Genetic</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015870">Gene Expression</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018811">Maternal Exposure</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018812">Paternal Exposure</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010920">Placenta</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010922">Placenta Diseases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011247">Pregnancy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D047928">Premature Birth</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011297">Prenatal Exposure Delayed Effects</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011980">Receptors, Progesterone</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013723">Teratogens</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013749">Tetrachlorodibenzodioxin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">NIHMS253696</OtherID>
        <OtherID Source="NLM">PMC3075349</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2010</Year>
                <Month>5</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2010</Year>
                <Month>10</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2010</Year>
                <Month>11</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2010</Year>
                <Month>11</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2010</Year>
                <Month>11</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2010</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2011</Year>
                <Month>7</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0890-6238(10)00327-8</ArticleId>
            <ArticleId IdType="doi">10.1016/j.reprotox.2010.11.003</ArticleId>
            <ArticleId IdType="pubmed">21093581</ArticleId>
            <ArticleId IdType="pmc">PMC3075349</ArticleId>
            <ArticleId IdType="mid">NIHMS253696</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">24657529</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>09</Month>
            <Day>19</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2015</Year>
            <Month>05</Month>
            <Day>31</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-3169</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>230</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Oct</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Toxicology letters</Title>
                <ISOAbbreviation>Toxicol. Lett.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Increased susceptibility to hyperoxic lung injury and alveolar simplification in newborn rats by prenatal administration of benzo[a]pyrene.</ArticleTitle>
            <Pagination>
                <MedlinePgn>322-32</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.toxlet.2014.03.006</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S0378-4274(14)00127-1</ELocationID>
            <Abstract>
                <AbstractText>Maternal smoking is one of the risk factors for preterm birth and for the development of bronchopulmonary dysplasia (BPD). In this study, we tested the hypothesis that prenatal exposure of rats to benzo[a]pyrene (BP), a component of cigarette smoke, will result in increased susceptibility of newborns to oxygen-mediated lung injury and alveolar simplification, and that cytochrome P450 (CYP)1A and 1B1 enzymes and oxidative stress mechanistically contribute to this phenomenon. Timed pregnant Fisher 344 rats were administered BP (25 mg/kg) or the vehicle corn oil (CO) on gestational days 18, 19 and 20, and newborn rats were either maintained in room air or exposed to hyperoxia (85% O2) for 7 or 14 days. Hyperoxic newborn rats prenatally exposed to the vehicle CO showed lung injury and alveolar simplification, and inflammation, and these effects were potentiated in rats that were prenatally exposed to BP. Prenatal exposure to BP, followed by hyperoxia, also resulted in significant modulation of hepatic and pulmonary cytochrome P450 (CYP)1A and 1B1 enzymes at PND 7-14. These rats displayed significant oxidative stress in lungs at postnatal day (PND) 14, as evidenced by increased levels of the F2-isoprostane 8-iso-PGF2. Furthermore, these animals showed BP-derived DNA adducts and oxidative DNA adducts in the lung. In conclusion, our results show increased susceptibility of newborns to oxygen-mediated lung injury and alveolar simplification following maternal exposure to BP, and our results suggest that modulation of CYP1A/1B1 enzymes, increases in oxidative stress, and BP-DNA adducts contributed to this phenomenon.</AbstractText>
                <CopyrightInformation>Copyright  2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Thakur</LastName>
                    <ForeName>Vijay S</ForeName>
                    <Initials>VS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatrics, Section of Neonatology, Texas Children's Hospital, Baylor College of Medicine, 1102 Bates Avenue, MC: FC530.01, Houston, TX 77030, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liang</LastName>
                    <ForeName>Yanhong W</ForeName>
                    <Initials>YW</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatrics, Section of Neonatology, Texas Children's Hospital, Baylor College of Medicine, 1102 Bates Avenue, MC: FC530.01, Houston, TX 77030, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lingappan</LastName>
                    <ForeName>Krithika</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatrics, Section of Neonatology, Texas Children's Hospital, Baylor College of Medicine, 1102 Bates Avenue, MC: FC530.01, Houston, TX 77030, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jiang</LastName>
                    <ForeName>Weiwu</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatrics, Section of Neonatology, Texas Children's Hospital, Baylor College of Medicine, 1102 Bates Avenue, MC: FC530.01, Houston, TX 77030, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Lihua</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatrics, Section of Neonatology, Texas Children's Hospital, Baylor College of Medicine, 1102 Bates Avenue, MC: FC530.01, Houston, TX 77030, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barrios</LastName>
                    <ForeName>Roberto</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology and Genomic Medicine, The Methodist Hospital Physician Organization, 6565 Fannin Street, Suite M227, Houston, TX 77030, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhou</LastName>
                    <ForeName>Guodong</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Biotechnology, Texas A&amp;M University Health Science Center, Houston, TX 77030, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guntupalli</LastName>
                    <ForeName>Bharath</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatrics, Section of Neonatology, Texas Children's Hospital, Baylor College of Medicine, 1102 Bates Avenue, MC: FC530.01, Houston, TX 77030, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shivanna</LastName>
                    <ForeName>Binoy</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatrics, Section of Neonatology, Texas Children's Hospital, Baylor College of Medicine, 1102 Bates Avenue, MC: FC530.01, Houston, TX 77030, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Maturu</LastName>
                    <ForeName>Paramahamsa</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatrics, Section of Neonatology, Texas Children's Hospital, Baylor College of Medicine, 1102 Bates Avenue, MC: FC530.01, Houston, TX 77030, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Welty</LastName>
                    <ForeName>Stephen E</ForeName>
                    <Initials>SE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatrics, Section of Neonatology, Texas Children's Hospital, Baylor College of Medicine, 1102 Bates Avenue, MC: FC530.01, Houston, TX 77030, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moorthy</LastName>
                    <ForeName>Bhagavatula</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatrics, Section of Neonatology, Texas Children's Hospital, Baylor College of Medicine, 1102 Bates Avenue, MC: FC530.01, Houston, TX 77030, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Couroucli</LastName>
                    <ForeName>Xanthi I</ForeName>
                    <Initials>XI</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatrics, Section of Neonatology, Texas Children's Hospital, Baylor College of Medicine, 1102 Bates Avenue, MC: FC530.01, Houston, TX 77030, USA. Electronic address: xanthic@bcm.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>P30 ES023512</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 ES-009132</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 ES-019689</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 ES009132</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 ES019689</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 HL-087174</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 HL-088343</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 HL-112516</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 HL087174</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 HL088343</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 HL112516</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>03</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Toxicol Lett</MedlineTA>
            <NlmUniqueID>7709027</NlmUniqueID>
            <ISSNLinking>0378-4274</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018736">DNA Adducts</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>3417WMA06D</RegistryNumber>
                <NameOfSubstance UI="D001564">Benzo(a)pyrene</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.14.1</RegistryNumber>
                <NameOfSubstance UI="D019363">Cytochrome P-450 CYP1A1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.14.1</RegistryNumber>
                <NameOfSubstance UI="D065633">Cytochrome P-450 CYP1B1</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 1988 Jun 1;48(11):2946-54</RefSource>
                <PMID Version="1">3284639</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pulm Pharmacol Ther. 2000;13(4):149-55</RefSource>
                <PMID Version="1">10930353</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacol Toxicol. 1991 Sep;69(3):178-88</RefSource>
                <PMID Version="1">1796059</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharmacol Exp Ther. 2000 Feb;292(2):553-60</RefSource>
                <PMID Version="1">10640292</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicology. 2013 Dec 6;314(1):30-8</RefSource>
                <PMID Version="1">24025706</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Semin Neonatol. 2000 Aug;5(3):231-41</RefSource>
                <PMID Version="1">10956448</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Pharmacol. 2002 Mar;61(3):507-15</RefSource>
                <PMID Version="1">11854430</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Crit Care Med. 2002 Dec 15;166(12 Pt 2):S25-30</RefSource>
                <PMID Version="1">12471085</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16713-8</RefSource>
                <PMID Version="1">12482927</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Perinat Med. 2004;32(3):272-7</RefSource>
                <PMID Version="1">15188804</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharmacol Exp Ther. 2004 Aug;310(2):512-9</RefSource>
                <PMID Version="1">15123765</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 1981 Nov 10;256(21):10986-92</RefSource>
                <PMID Version="1">7287745</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 1986 Jun;46(6):3046-54</RefSource>
                <PMID Version="1">3698023</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Carcinogenesis. 1986 Sep;7(9):1543-51</RefSource>
                <PMID Version="1">3017601</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Chem Res Toxicol. 1994 Jul-Aug;7(4):471-81</RefSource>
                <PMID Version="1">7981411</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Placenta. 1995 Apr;16(3):317-20</RefSource>
                <PMID Version="1">7638112</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Invest. 1995 Oct;96(4):2083-9</RefSource>
                <PMID Version="1">7560103</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Health Perspect. 1996 May;104 Suppl 3:625-7</RefSource>
                <PMID Version="1">8781394</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Paediatr Perinat Epidemiol. 1997 Apr;11(2):140-51</RefSource>
                <PMID Version="1">9131707</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Acta Paediatr. 1997 Dec;86(12):1277-82</RefSource>
                <PMID Version="1">9475300</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pediatr. 1998 Feb;132(2):349-51</RefSource>
                <PMID Version="1">9506655</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Physiol. 1998 Jul;275(1 Pt 1):L110-7</RefSource>
                <PMID Version="1">9688942</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mutat Res. 1999 Jul 15;443(1-2):139-47</RefSource>
                <PMID Version="1">10415437</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Prostaglandins Other Lipid Mediat. 1999 Jul;57(5-6):319-31</RefSource>
                <PMID Version="1">10480486</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Crit Care Med. 1999 Oct;160(4):1333-46</RefSource>
                <PMID Version="1">10508826</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Appl Pharmacol. 2004 Dec 15;201(3):295-302</RefSource>
                <PMID Version="1">15582647</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Appl Pharmacol. 2005 Aug 1;206(1):73-93</RefSource>
                <PMID Version="1">15963346</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Sci. 2005 Sep;87(1):204-12</RefSource>
                <PMID Version="1">15958656</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Appl Pharmacol. 2005 Nov 15;209(1):28-38</RefSource>
                <PMID Version="1">15885734</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int Arch Occup Environ Health. 2007 Oct;81(1):115-21</RefSource>
                <PMID Version="1">17394008</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Pharmacol Ther. 2008 Apr;83(4):542-50</RefSource>
                <PMID Version="1">17928820</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Semin Fetal Neonatal Med. 2010 Aug;15(4):223-9</RefSource>
                <PMID Version="1">20430708</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Health Perspect. 2010 Aug;118(8):1155-64</RefSource>
                <PMID Version="1">20444669</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pediatrics. 2009 Sep;124(3):e439-49</RefSource>
                <PMID Version="1">19661049</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Public Health Nutr. 2010 Dec;13(12):2034-43</RefSource>
                <PMID Version="1">20444315</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pediatrics. 2011 Jan;127(1):e106-16</RefSource>
                <PMID Version="1">21149431</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Appl Pharmacol. 2011 Oct 15;256(2):83-94</RefSource>
                <PMID Version="1">21745492</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Perinatol. 2011 Oct;31(10):635-40</RefSource>
                <PMID Version="1">21311503</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2011;6(10):e26589</RefSource>
                <PMID Version="1">22066002</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicology. 2012 May 16;295(1-3):56-67</RefSource>
                <PMID Version="1">22374506</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Early Hum Dev. 2012 Jul;88(7):509-15</RefSource>
                <PMID Version="1">22236557</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Endocrinology. 2012 Aug;153(8):3960-71</RefSource>
                <PMID Version="1">22700766</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Health. 2013;12:6</RefSource>
                <PMID Version="1">23320899</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pediatr Res. 2013 Apr;73(4 Pt 2):514-22</RefSource>
                <PMID Version="1">23314295</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Expo Sci Environ Epidemiol. 2013 Jul;23(4):371-7</RefSource>
                <PMID Version="1">23299301</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Cell Mol Biol. 2013 Aug;49(2):180-9</RefSource>
                <PMID Version="1">23492192</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Health Perspect. 2013 Aug;121(8):957-64</RefSource>
                <PMID Version="1">23757602</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Int. 2013 Oct;60:217-23</RefSource>
                <PMID Version="1">24071023</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 1989 Apr 1;49(7):1676-81</RefSource>
                <PMID Version="1">2538231</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000831">Animals, Newborn</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001564">Benzo(a)pyrene</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019363">Cytochrome P-450 CYP1A1</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D065633">Cytochrome P-450 CYP1B1</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018736">DNA Adducts</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005333">Fetus</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018496">Hyperoxia</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D055370">Lung Injury</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011247">Pregnancy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011650">Pulmonary Alveoli</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011916">Rats, Inbred F344</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">NIHMS592823 [Available on 10/15/15]</OtherID>
        <OtherID Source="NLM">PMC4169345 [Available on 10/15/15]</OtherID>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Alveolar simplification</Keyword>
            <Keyword MajorTopicYN="N">Cytochrome P4501A1/1A2/1B1</Keyword>
            <Keyword MajorTopicYN="N">Hyperoxic lung injury</Keyword>
            <Keyword MajorTopicYN="N">Maternal benzo[a]pyrene</Keyword>
            <Keyword MajorTopicYN="N">Newborn rat</Keyword>
            <Keyword MajorTopicYN="N">Oxidative stress</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>10</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>12</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pmc-release">
                <Year>2015</Year>
                <Month>10</Month>
                <Day>15</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24657529</ArticleId>
            <ArticleId IdType="pii">S0378-4274(14)00127-1</ArticleId>
            <ArticleId IdType="doi">10.1016/j.toxlet.2014.03.006</ArticleId>
            <ArticleId IdType="pmc">PMC4169345</ArticleId>
            <ArticleId IdType="mid">NIHMS592823</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">6851197</PMID>
        <DateCreated>
            <Year>1983</Year>
            <Month>07</Month>
            <Day>08</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1983</Year>
            <Month>07</Month>
            <Day>08</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0300-0664</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>18</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>1983</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical endocrinology</Title>
                <ISOAbbreviation>Clin. Endocrinol. (Oxf)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Corticosteroid myopathy: a clinical and pathological study.</ArticleTitle>
            <Pagination>
                <MedlinePgn>155-66</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>In six patients with Cushing's syndrome and three with steroid myopathy, the clinical, functional, biochemical and structural characteristics of myopathy are described. Proximal muscle weakness occurred in all the patients, preferentially affected the lower limbs and was accompanied by muscle wasting in all but one patient. Force measurements confirmed quadriceps weakness in every patient. Vastus lateralis muscle biopsies showed light microscopic abnormalities in two of three patients with steroid myopathy and one of five patients with Cushing's syndrome. Type II fibre atrophy was the commonest abnormality. Reduced type II mean fibre areas occurred in all the patients with steroid myopathy and were common in Cushing's syndrome patients. Type I mean fibre areas were also reduced in two of the former group and one of the latter group and two further patients in this group had areas at the lower end of the normal range. Abnormalities in electron microscopy, mitochondrial function tests and chemical content of skeletal muscle were frequent and are described and discussed. A plasma creatine kinase activity (CK) at the lower end of the normal range, a myopathic electromyogram (EMG) and a raised 24-h urinary 3-methylhistidine/creatinine ratio on a creatine free diet were other characteristic findings in both groups of patients.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Khaleeli</LastName>
                    <ForeName>A A</ForeName>
                    <Initials>AA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Edwards</LastName>
                    <ForeName>R H</ForeName>
                    <Initials>RH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gohil</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McPhail</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rennie</LastName>
                    <ForeName>M J</ForeName>
                    <Initials>MJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Round</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ross</LastName>
                    <ForeName>E J</ForeName>
                    <Initials>EJ</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>ENGLAND</Country>
            <MedlineTA>Clin Endocrinol (Oxf)</MedlineTA>
            <NlmUniqueID>0346653</NlmUniqueID>
            <ISSNLinking>0300-0664</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>VB0R961HZT</RegistryNumber>
                <NameOfSubstance UI="D011241">Prednisone</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003480">Cushing Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008854">Microscopy, Electron</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009132">Muscles</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000648">ultrastructure</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009135">Muscular Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011241">Prednisone</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1983</Year>
                <Month>2</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1983</Year>
                <Month>2</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1983</Year>
                <Month>2</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6851197</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">15470335</PMID>
        <DateCreated>
            <Year>2004</Year>
            <Month>10</Month>
            <Day>07</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2004</Year>
            <Month>10</Month>
            <Day>29</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2006</Year>
            <Month>11</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0009-9236</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>76</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2004</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical pharmacology and therapeutics</Title>
                <ISOAbbreviation>Clin. Pharmacol. Ther.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>QT interval prolongation after oxytocin bolus during surgical induced abortion.</ArticleTitle>
            <Pagination>
                <MedlinePgn>359-64</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although oxytocin, a uterotonic agent, may cause short-term vasodilation that results in severe hypotension, it is still routinely given as an intravenous bolus injection during surgical suction curettage. Two reported cases of ventricular tachycardia after oxytocin bolus in patients with long QT interval syndrome led us to assess the effect of oxytocin on QT interval.</AbstractText>
                <AbstractText Label="METHOD" NlmCategory="METHODS">Thirty-eight healthy women scheduled for a surgical suction curettage with general anesthesia were enrolled. General anesthesia was induced by propofol and maintained by either propofol (n = 18) or sevoflurane (n = 20). Electrocardiographic recordings were obtained before and at 1, 2, 3, and 5 minutes after a 10-U intravenous bolus of oxytocin.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Intravenous oxytocin induced a pronounced QTc interval prolongation of 41 +/- 21 ms ( P &lt; .0001), which was maximal 1 minute after administration. The QTc interval returned to control values 3 minutes after oxytocin bolus. Oxytocin bolus also induced an increase in heart rate of 19 +/- 10 beats/min and a significant decrease in systolic arterial pressure of 11 +/- 9 mm Hg (both P &lt; .0001). The drug used to maintain anesthesia was not an independent factor of QT interval prolongation in ANOVA analysis.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Oxytocin intravenous bolus induced a large and transient QTc interval prolongation, suggesting that it may lead to proarrhythmia in circumstances favoring QTc interval increase.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Charbit</LastName>
                    <ForeName>Beny</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departent of Anesthesiology and Intensive Care, Beaujon University Hospital, Assistance Publique, Hpitaux de Paris, Clichy, France. beny.charbit@bjn.ap-hop-paris.fr</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Funck-Brentano</LastName>
                    <ForeName>Christian</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Samain</LastName>
                    <ForeName>Emmanuel</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jannier-Guillou</LastName>
                    <ForeName>Virginie</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Albaladejo</LastName>
                    <ForeName>Pierre</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Marty</LastName>
                    <ForeName>Jean</ForeName>
                    <Initials>J</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016430">Clinical Trial</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Clin Pharmacol Ther</MedlineTA>
            <NlmUniqueID>0372741</NlmUniqueID>
            <ISSNLinking>0009-9236</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010120">Oxytocics</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>50-56-6</RegistryNumber>
                <NameOfSubstance UI="D010121">Oxytocin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Clin Pharmacol Ther. 2004 Oct;76(4):287-9</RefSource>
                <PMID Version="1">15470327</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D000028">Abortion, Induced</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004562">Electrocardiography</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007262">Infusions, Intravenous</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008133">Long QT Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010120">Oxytocics</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010121">Oxytocin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011247">Pregnancy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014619">Vacuum Curettage</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2004</Year>
                <Month>10</Month>
                <Day>8</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2004</Year>
                <Month>10</Month>
                <Day>30</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2004</Year>
                <Month>10</Month>
                <Day>8</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0009923604002012</ArticleId>
            <ArticleId IdType="doi">10.1016/j.clpt.2004.06.005</ArticleId>
            <ArticleId IdType="pubmed">15470335</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">17327368</PMID>
        <DateCreated>
            <Year>2007</Year>
            <Month>06</Month>
            <Day>05</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2007</Year>
            <Month>07</Month>
            <Day>30</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0193-1849</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>292</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2007</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of physiology. Endocrinology and metabolism</Title>
                <ISOAbbreviation>Am. J. Physiol. Endocrinol. Metab.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Hypertension caused by prenatal testosterone excess in female sheep.</ArticleTitle>
            <Pagination>
                <MedlinePgn>E1837-41</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Polycystic ovary syndrome (PCOS), a leading cause of infertility, affects approximately 10% of women of reproductive age. The etiology and pathophysiology of PCOS are poorly understood. PCOS is multifaceted and includes reproductive abnormalities and components of the metabolic syndrome such as insulin resistance, obesity, dyslipidemia, and hypertension. Exposure to excess testosterone (T) during the prenatal period may predispose individuals to PCOS phenotype. The goal of this study was to determine whether hypertension and dyslipidemia occur in a well-characterized model of PCOS produced by prenatal treatment of sheep with T. Radiotelemetry was used to measure blood pressure over a 24-h period in conscious, undisturbed animals. To normalize circulating estradiol levels across treatment, control (n = 4) and prenatal T-treated (100 mg T propionate im twice weekly from days 30 to 90 of fetal life, n = 4) 2-yr-old females were ovariectomized, instrumented with a radiotelemetry transmitter, and clamped with early follicular phase levels of estrogen using an implant. Six days later, a 24-h recording period commenced. Prenatal T-treated sheep were hypertensive compared with control sheep, and heart rate tended to be higher. T-treated sheep had hyperglycemia, insulin resistance, hypernatremia, and hyperchloremia, and both total and LDL cholesterol tended to be higher. Plasma aldosterone and epinephrine were significantly lower in T-treated sheep, whereas norepinephrine was unchanged. This first-ever use of radiotelemetric blood pressure recordings in sheep demonstrates that mild hypertension, a risk factor reported in some women with PCOS, is also a feature of the sheep model of PCOS produced by prenatal T treatment.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>King</LastName>
                    <ForeName>Andrew J</ForeName>
                    <Initials>AJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Deparetment of Pharmacology and Toxicology, B440 Life Sciences, Michigan State University, East Lansing, MI 48824, USA. kingand@msu.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Olivier</LastName>
                    <ForeName>N Bari</ForeName>
                    <Initials>NB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mohankumar</LastName>
                    <ForeName>P S</ForeName>
                    <Initials>PS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>James S</ForeName>
                    <Initials>JS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Padmanabhan</LastName>
                    <ForeName>Vasantha</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fink</LastName>
                    <ForeName>Gregory D</ForeName>
                    <Initials>GD</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>P01-HD-44232</GrantID>
                    <Acronym>HD</Acronym>
                    <Agency>NICHD NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2007</Year>
                <Month>02</Month>
                <Day>27</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Am J Physiol Endocrinol Metab</MedlineTA>
            <NlmUniqueID>100901226</NlmUniqueID>
            <ISSNLinking>0193-1849</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002712">Chlorides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>4964P6T9RB</RegistryNumber>
                <NameOfSubstance UI="D000450">Aldosterone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>97C5T2UQ7J</RegistryNumber>
                <NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WI93Z9138A</RegistryNumber>
                <NameOfSubstance UI="D043343">Testosterone Propionate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>YKH834O4BH</RegistryNumber>
                <NameOfSubstance UI="D004837">Epinephrine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000450">Aldosterone</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001794">Blood Pressure</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002712">Chlorides</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002784">Cholesterol</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D004195">Disease Models, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D050171">Dyslipidemias</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004837">Epinephrine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006339">Heart Rate</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006943">Hyperglycemia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006955">Hypernatremia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006973">Hypertension</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007333">Insulin Resistance</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011085">Polycystic Ovary Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011247">Pregnancy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D011297">Prenatal Exposure Delayed Effects</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D012756">Sheep</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D043343">Testosterone Propionate</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2007</Year>
                <Month>2</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2007</Year>
                <Month>3</Month>
                <Day>1</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2007</Year>
                <Month>7</Month>
                <Day>31</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2007</Year>
                <Month>3</Month>
                <Day>1</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">00668.2006</ArticleId>
            <ArticleId IdType="doi">10.1152/ajpendo.00668.2006</ArticleId>
            <ArticleId IdType="pubmed">17327368</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">21440839</PMID>
        <DateCreated>
            <Year>2011</Year>
            <Month>03</Month>
            <Day>28</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2011</Year>
            <Month>06</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0895-3988</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>24</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2011</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Biomedical and environmental sciences : BES</Title>
                <ISOAbbreviation>Biomed. Environ. Sci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effects of mercury on the structure and activity of BLM642-1290 recombinant helicase.</ArticleTitle>
            <Pagination>
                <MedlinePgn>47-55</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3967/0895-3988.2011.01.006</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Bloom's syndrome is an autosomal recessive disorder characterized by genomic instability and a predisposition to many cancers. Mutations of the BLM gene (encoding a BLM helicase) may form a structure of the etiology of this disease. As a global pollutant, mercury poses a major threat to human health. The current study was conducted to elucidate the effects of Hg(2+) on the structure and activity of BLM642-1290 recombinant helicase, and to further explore the molecular mechanisms of mercury toxicity to the DNA helicase.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">The effects of Hg(2+) on biological activity and structure of BLM642-1290 recombinant helicase were determined by fluorescence polarized, ultraviolet spectroscopic, and free-phosphorus assay technologies, respectively.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The helicase activity, the DNA-binding activity, and the ATPase activity of BLM642-1290 recombinant helicase were inhibited by Hg(2+) treatment. The LMCT (ligand-to-metal charge transition) peaks of the helicase were enhanced with the increase of the Hg(2+) level. The LMCT peaks of the same concentration of helicase gradually increased over time.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The biological activity of BLM642-1290 recombinant helicase is inhibited by Hg(2+) treatment. The conformation of the helicase is significantly altered by Hg(2+). There exist two binding sites between Hg(2+) and the helicase, which are located in the amino acid residues 1063-1066 and 940-944 of the helicase, respectively.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Xiang</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Guizhou Key Laboratory of Animal Genetics, Breeding and Reproduction, College of Animal Science, Guizhou University, Guiyang 550025, Guizhou, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Luo</LastName>
                    <ForeName>Heng</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Duan</LastName>
                    <ForeName>Lixia</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Qinghe</ForeName>
                    <Initials>Q</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Yong</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Houqiang</ForeName>
                    <Initials>H</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Biomed Environ Sci</MedlineTA>
            <NlmUniqueID>8909524</NlmUniqueID>
            <ISSNLinking>0895-3988</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017931">DNA Primers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.6.1.-</RegistryNumber>
                <NameOfSubstance UI="D000251">Adenosine Triphosphatases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.6.1.-</RegistryNumber>
                <NameOfSubstance UI="C097151">Bloom syndrome protein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.6.4.12</RegistryNumber>
                <NameOfSubstance UI="D053484">RecQ Helicases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>FXS1BY2PGL</RegistryNumber>
                <NameOfSubstance UI="D008628">Mercury</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000251">Adenosine Triphosphatases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001483">Base Sequence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017931">DNA Primers</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005454">Fluorescence Polarization</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008628">Mercury</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011487">Protein Conformation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D053484">RecQ Helicases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011994">Recombinant Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013056">Spectrophotometry, Ultraviolet</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013329">Structure-Activity Relationship</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2010</Year>
                <Month>2</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2010</Year>
                <Month>12</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2011</Year>
                <Month>3</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2011</Year>
                <Month>3</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2011</Year>
                <Month>6</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0895-3988(11)60020-2</ArticleId>
            <ArticleId IdType="doi">10.3967/0895-3988.2011.01.006</ArticleId>
            <ArticleId IdType="pubmed">21440839</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">16458197</PMID>
        <DateCreated>
            <Year>2006</Year>
            <Month>02</Month>
            <Day>06</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2006</Year>
            <Month>05</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0891-5849</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>40</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2006</Year>
                        <Month>Feb</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Free radical biology &amp; medicine</Title>
                <ISOAbbreviation>Free Radic. Biol. Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Retinal degeneration from oxidative damage.</ArticleTitle>
            <Pagination>
                <MedlinePgn>660-9</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Paraquat, a herbicide that generates reactive oxygen species, has been used to probe the oxidative defense systems of lung. In this study, we investigated the effects of paraquat in the retina. There was no significant decline in electroretinogram (ERG) a- or b-wave amplitudes after intravitreous injection of 1 mul of 0.5 mM paraquat in C57BL/6 mice, but loss of ERG function occurred after injection of 0.75 or 1 mM paraquat. Histology in paraquat-injected eyes showed condensation of chromatin and thinning of the inner and outer nuclear layers indicating cell death, and terminal deoxynucleotidyl transferase-mediated duTP-biotinide end labeling demonstrated that one mechanism of cell death was apoptosis. Fluorescence in the retina and retinal pigmented epithelium after intraocular injection of paraquat followed by perfusion with hydroethidine indicated high levels of superoxide radicals, and oxidative damage was demonstrated by staining for acrolein and enzyme-linked immunosorbent assay for carbonyl adducts. Paraquat-induced damage to the outer nuclear layer was greater in BALB/c mice than in C57BL/6 mice, suggesting strain differences in the oxidative defense system of photoreceptors and/or other modifier genes. Intravitreous injection of paraquat provides a new model of oxidative damage-induced retinal degeneration that is likely to be useful for testing new antioxidant treatments.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Cingolani</LastName>
                    <ForeName>Celia</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Ophthalmology and Department of Neuroscience, The Johns Hopkins University School of Medicine, Maumenee 719, 600 N. Wolfe Street, Baltimore, MD 21287-9277, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rogers</LastName>
                    <ForeName>Brian</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lu</LastName>
                    <ForeName>Lili</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kachi</LastName>
                    <ForeName>Shu</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shen</LastName>
                    <ForeName>Jikui</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Campochiaro</LastName>
                    <ForeName>Peter A</ForeName>
                    <Initials>PA</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>EY05951</GrantID>
                    <Acronym>EY</Acronym>
                    <Agency>NEI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>EY12609</GrantID>
                    <Acronym>EY</Acronym>
                    <Agency>NEI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P30EY1765</GrantID>
                    <Acronym>EY</Acronym>
                    <Agency>NEI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2005</Year>
                <Month>10</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Free Radic Biol Med</MedlineTA>
            <NlmUniqueID>8709159</NlmUniqueID>
            <ISSNLinking>0891-5849</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002843">Chromatin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006540">Herbicides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>11062-77-4</RegistryNumber>
                <NameOfSubstance UI="D013481">Superoxides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>PLG39H7695</RegistryNumber>
                <NameOfSubstance UI="D010269">Paraquat</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002843">Chromatin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004596">Electroretinography</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006540">Herbicides</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010084">Oxidation-Reduction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D018384">Oxidative Stress</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010269">Paraquat</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010786">Photoreceptor Cells</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010857">Pigment Epithelium of Eye</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000166">cytology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012160">Retina</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000166">cytology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012162">Retinal Degeneration</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013481">Superoxides</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2005</Year>
                <Month>2</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2005</Year>
                <Month>9</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2005</Year>
                <Month>9</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2005</Year>
                <Month>10</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2006</Year>
                <Month>2</Month>
                <Day>7</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2006</Year>
                <Month>5</Month>
                <Day>4</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2006</Year>
                <Month>2</Month>
                <Day>7</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0891-5849(05)00552-6</ArticleId>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2005.09.032</ArticleId>
            <ArticleId IdType="pubmed">16458197</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">6119681</PMID>
        <DateCreated>
            <Year>1982</Year>
            <Month>03</Month>
            <Day>22</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1982</Year>
            <Month>03</Month>
            <Day>22</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0301-0244</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>33</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>1981</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Polish journal of pharmacology and pharmacy</Title>
                <ISOAbbreviation>Pol J Pharmacol Pharm</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Central action of narcotic analgesics. VIII. The effect of dopaminergic stimulants on the action of analgesics in rats.</ArticleTitle>
            <Pagination>
                <MedlinePgn>273-82</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>We investigated the influence of apomorphine, amphetamine, amantadine, dimethylaminoadamantane, nomifensine, ergometrine and beta-phenylethylamine on cataleptogenic and antinociceptive action of analgesics in rats. Nomifensine, apomorphine, beta-phenylethylamine, amantadine and ergometrine antagonized the catalepsy induced by morphine and codeine. Catalepsy induced by fentanyl was depressed only by nomifensine and apomorphine. Amphetamine only slightly antagonized the analgesic-induced catalepsy and the effects were not dose-dependent. Dimethylaminoadamantane did not antagonize catalepsy at all. Antinociceptive action of morphine and codeine was antagonized by apomorphine and amphetamine. Ergometrine counteracted the action of morphine, and beta-phenylethylamine decreased the action of pentazocine. The results suggest that: 1. There are differences in the mechanism of cataleptogenic action of the opiates (morphine and codeine) and fentanyl; 2. Catalepsy after analgesia differs from the catalepsy produced by neuroleptics in respect of interaction with such drugs as amphetamine, apomorphine or dimethylaminoadamantane. Analgesic-induced catalepsy seems to depend on the presynaptic inhibition of dopaminergic neurotransmission; 3. Stimulation of the central dopaminergic system in rat brain either does not change or weakly antagonizes the action of analgesics in the hot plate test.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Malec</LastName>
                    <ForeName>D</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Langwiski</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>POLAND</Country>
            <MedlineTA>Pol J Pharmacol Pharm</MedlineTA>
            <NlmUniqueID>0366561</NlmUniqueID>
            <ISSNLinking>0301-0244</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000700">Analgesics</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000701">Analgesics, Opioid</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>76I7G6D29C</RegistryNumber>
                <NameOfSubstance UI="D009020">Morphine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>CK833KGX7E</RegistryNumber>
                <NameOfSubstance UI="D000661">Amphetamine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>N21FAR7B4S</RegistryNumber>
                <NameOfSubstance UI="D001058">Apomorphine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>Q830PW7520</RegistryNumber>
                <NameOfSubstance UI="D003061">Codeine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>UF599785JZ</RegistryNumber>
                <NameOfSubstance UI="D005283">Fentanyl</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>VTD58H1Z2X</RegistryNumber>
                <NameOfSubstance UI="D004298">Dopamine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000661">Amphetamine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000700">Analgesics</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000701">Analgesics, Opioid</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001058">Apomorphine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002375">Catalepsy</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003061">Codeine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004298">Dopamine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004347">Drug Interactions</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005283">Fentanyl</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009020">Morphine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011919">Rats, Inbred Strains</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1981</Year>
                <Month>10</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1981</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1981</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6119681</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">22200898</PMID>
        <DateCreated>
            <Year>2012</Year>
            <Month>01</Month>
            <Day>19</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2012</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-7225</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>23</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2012</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer causes &amp; control : CCC</Title>
                <ISOAbbreviation>Cancer Causes Control</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Maternal smoking during pregnancy, genetic polymorphisms of metabolic enzymes, and childhood acute leukemia: the ESCALE study (SFCE).</ArticleTitle>
            <Pagination>
                <MedlinePgn>329-45</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10552-011-9882-9</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">This study explored interactions between prenatal exposure to maternal smoking and polymorphisms in metabolic genes in the risk of childhood acute leukemia (AL).</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">The data were generated by the ESCALE study, which included 764 AL cases and 1,681 controls in 2003-2004. The data on maternal smoking during pregnancy were obtained by standardized telephone interview of the cases' and controls' mothers. The genotypes CYP1A1*2A/2B (rs4646903), CYP2E1*5 (rs2031920, rs3813867), NQO1*2 (rs1800566), NAT2*5 (rs1801280), and EPHX1 exon 3 (rs1051740) and exon 4 (rs2234922) were obtained using a high-throughput platform and imputation for untyped polymorphisms. The analyses were restricted to the 493 cases (433 cases of lymphoblastic (ALL) and 51 of myeloblastic (AML) leukemia) and 441 controls with at least 2 grandparents born in Europe, who were genotyped with individual call rates greater than 95%. Odds ratios were estimated by logistic regression in case-control analyses and, for gene-gene and gene-environment interactions, by case-only analyses.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">ALL and AML were not associated with either maternal smoking during pregnancy or candidate polymorphisms in CYP1A1, CYP2E1, EPHX1, and NQO1. Carrying two NAT2*5 alleles was significantly associated with ALL (OR = 1.8 [1.3-2.5]). The analyses also suggested an interaction between three genes involved in benzene metabolism CYP2E1, NQO1, and EPHX1. There was no interaction between maternal smoking and any of the polymorphisms under study.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The ESCALE study did not evidence the interaction between CYP1A1*2A/2B and maternal smoking suggested previously. The association with NAT2*5 and the gene-gene interactions need to be replicated.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bonaventure</LastName>
                    <ForeName>Audrey</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Inserm, UMRS 1018, CESP, Team 6 Environmental Epidemiology of Cancer, Villejuif, France. audrey.bonaventure@inserm.fr</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Goujon-Bellec</LastName>
                    <ForeName>Stphanie</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rudant</LastName>
                    <ForeName>Jrmie</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Orsi</LastName>
                    <ForeName>Laurent</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Leverger</LastName>
                    <ForeName>Guy</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Baruchel</LastName>
                    <ForeName>Andr</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bertrand</LastName>
                    <ForeName>Yves</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nelken</LastName>
                    <ForeName>Brigitte</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pasquet</LastName>
                    <ForeName>Marlne</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Michel</LastName>
                    <ForeName>Grard</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sirvent</LastName>
                    <ForeName>Nicolas</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bordigoni</LastName>
                    <ForeName>Pierre</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ducassou</LastName>
                    <ForeName>Stphane</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rialland</LastName>
                    <ForeName>Xavier</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zelenika</LastName>
                    <ForeName>Diana</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hmon</LastName>
                    <ForeName>Denis</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Clavel</LastName>
                    <ForeName>Jacqueline</ForeName>
                    <Initials>J</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2011</Year>
                <Month>12</Month>
                <Day>27</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Cancer Causes Control</MedlineTA>
            <NlmUniqueID>9100846</NlmUniqueID>
            <ISSNLinking>0957-5243</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>9035-51-2</RegistryNumber>
                <NameOfSubstance UI="D003577">Cytochrome P-450 Enzyme System</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.14.1</RegistryNumber>
                <NameOfSubstance UI="C569463">CYP1A1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.14.1</RegistryNumber>
                <NameOfSubstance UI="C110332">CYP2F1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.14.1</RegistryNumber>
                <NameOfSubstance UI="D019363">Cytochrome P-450 CYP1A1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.6.5.2</RegistryNumber>
                <NameOfSubstance UI="D016660">NAD(P)H Dehydrogenase (Quinone)</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.6.5.2</RegistryNumber>
                <NameOfSubstance UI="C447479">NQO1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.3.2.-</RegistryNumber>
                <NameOfSubstance UI="D004851">Epoxide Hydrolases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.3.2.9</RegistryNumber>
                <NameOfSubstance UI="C522330">EPHX1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>J64922108F</RegistryNumber>
                <NameOfSubstance UI="D001554">Benzene</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000483">Alleles</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001554">Benzene</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016022">Case-Control Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002675">Child, Preschool</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019363">Cytochrome P-450 CYP1A1</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003577">Cytochrome P-450 Enzyme System</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004851">Epoxide Hydrolases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" Type="Geographic" UI="D005060">Europe</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005091">Exons</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D059647">Gene-Environment Interaction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020022">Genetic Predisposition to Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D055106">Genome-Wide Association Study</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005838">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015470">Leukemia, Myeloid, Acute</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016015">Logistic Models</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016660">NAD(P)H Dehydrogenase (Quinone)</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020641">Polymorphism, Single Nucleotide</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011247">Pregnancy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011252">Pregnancy Complications, Neoplastic</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011297">Prenatal Exposure Delayed Effects</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012907">Smoking</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2011</Year>
                <Month>8</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2011</Year>
                <Month>12</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2011</Year>
                <Month>12</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2011</Year>
                <Month>12</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2011</Year>
                <Month>12</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2012</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10552-011-9882-9</ArticleId>
            <ArticleId IdType="pubmed">22200898</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">15161764</PMID>
        <DateCreated>
            <Year>2004</Year>
            <Month>05</Month>
            <Day>26</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2004</Year>
            <Month>08</Month>
            <Day>04</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0012-1797</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>53</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2004</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Diabetes</Title>
                <ISOAbbreviation>Diabetes</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A new mouse model of type 2 diabetes, produced by N-ethyl-nitrosourea mutagenesis, is the result of a missense mutation in the glucokinase gene.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1577-83</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Here we report the first cloned N-ethyl-nitrosourea (ENU)-derived mouse model of diabetes. GENA348 was identified through free-fed plasma glucose measurement, being more than 2 SDs above the population mean of a cohort of &gt;1,201 male ENU mutant mice. The underlying gene was mapped to the maturity-onset diabetes of the young (MODY2) homology region of mouse chromosome 11 (logarithm of odds 6.0). Positional candidate gene analyses revealed an A to T transversion mutation in exon 9 of the glucokinase gene, resulting in an isoleucine to phenylalanine change at amino acid 366 (I366F). Heterozygous mutants have 67% of the enzyme activity of wild-type littermates (P &lt; 0.0012). Homozygous mutants have less enzyme activity (14% of wild-type activity) and are even less glucose tolerant. The GENA348 allele is novel because no mouse or human diabetes studies have described a mutation in the corresponding amino acid position. It is also the first glucokinase missense mutation reported in mice and is homozygous viable, unlike the global knockout mutations. This work demonstrates that ENU mutagenesis screens can be used to generate models of complex phenotypes, such as type 2 diabetes, that are directly relevant to human disease.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Toye</LastName>
                    <ForeName>Ayo A</ForeName>
                    <Initials>AA</Initials>
                    <AffiliationInfo>
                        <Affiliation>MRC Mammalian Genetics Unit, Medical Research Council, Harwell, Oxfordshire OX11 0RD UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moir</LastName>
                    <ForeName>Lee</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hugill</LastName>
                    <ForeName>Alison</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bentley</LastName>
                    <ForeName>Liz</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Quarterman</LastName>
                    <ForeName>Julie</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mijat</LastName>
                    <ForeName>Vesna</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hough</LastName>
                    <ForeName>Tertius</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Goldsworthy</LastName>
                    <ForeName>Michelle</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Haynes</LastName>
                    <ForeName>Alison</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hunter</LastName>
                    <ForeName>A Jacqueline</ForeName>
                    <Initials>AJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Browne</LastName>
                    <ForeName>Mick</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Spurr</LastName>
                    <ForeName>Nigel</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cox</LastName>
                    <ForeName>Roger D</ForeName>
                    <Initials>RD</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Diabetes</MedlineTA>
            <NlmUniqueID>0372763</NlmUniqueID>
            <ISSNLinking>0012-1797</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009153">Mutagens</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>04Y7590D77</RegistryNumber>
                <NameOfSubstance UI="D007532">Isoleucine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>47E5O17Y3R</RegistryNumber>
                <NameOfSubstance UI="D010649">Phenylalanine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.1.2</RegistryNumber>
                <NameOfSubstance UI="D005941">Glucokinase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>IY9XDZ35W2</RegistryNumber>
                <NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>JAC85A2161</RegistryNumber>
                <NameOfSubstance UI="D000225">Adenine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>P8M1T4190R</RegistryNumber>
                <NameOfSubstance UI="D005038">Ethylnitrosourea</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>QR26YLT7LT</RegistryNumber>
                <NameOfSubstance UI="D013941">Thymine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000225">Adenine</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000595">Amino Acid Sequence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019943">Amino Acid Substitution</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002874">Chromosome Mapping</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003924">Diabetes Mellitus, Type 2</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D004195">Disease Models, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005038">Ethylnitrosourea</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005941">Glucokinase</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005947">Glucose</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018149">Glucose Intolerance</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006579">Heterozygote</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006720">Homozygote</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007532">Isoleucine</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008817">Mice, Mutant Strains</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008969">Molecular Sequence Data</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009153">Mutagens</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D020125">Mutation, Missense</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010649">Phenylalanine</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013941">Thymine</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2004</Year>
                <Month>5</Month>
                <Day>27</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2004</Year>
                <Month>8</Month>
                <Day>5</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2004</Year>
                <Month>5</Month>
                <Day>27</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15161764</ArticleId>
            <ArticleId IdType="pii">53/6/1577</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">2559449</PMID>
        <DateCreated>
            <Year>1990</Year>
            <Month>03</Month>
            <Day>08</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1990</Year>
            <Month>03</Month>
            <Day>08</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0035-3787</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>145</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>1989</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Revue neurologique</Title>
                <ISOAbbreviation>Rev. Neurol. (Paris)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Painful legs and moving toes. Neuropathy caused by cytarabine].</ArticleTitle>
            <Pagination>
                <MedlinePgn>869-71</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>A new case of painful legs and moving toes syndrome is reported in a patient with a neuropathy due to high-doses of cytosine arabinoside (Ara C). A few cases of this complication have been reported. The neuropathy was sensory, axonal, and incompletely regressive. Carbamazepine had a dramatic effect on pain and involuntary movements.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Malapert</LastName>
                    <ForeName>D</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Dpartement de Neurosciences, CHU Henri Mondor, Crteil.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Degos</LastName>
                    <ForeName>J D</ForeName>
                    <Initials>JD</Initials>
                </Author>
            </AuthorList>
            <Language>fre</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D004740">English Abstract</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
            <VernacularTitle>Jambes douloureuses et orteils instables. Neuropathie induite par la cytarabine.</VernacularTitle>
        </Article>
        <MedlineJournalInfo>
            <Country>FRANCE</Country>
            <MedlineTA>Rev Neurol (Paris)</MedlineTA>
            <NlmUniqueID>2984779R</NlmUniqueID>
            <ISSNLinking>0035-3787</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>04079A1RDZ</RegistryNumber>
                <NameOfSubstance UI="D003561">Cytarabine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>33CM23913M</RegistryNumber>
                <NameOfSubstance UI="D002220">Carbamazepine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001369">Axons</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002220">Carbamazepine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003561">Cytarabine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007866">Leg</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000294">innervation</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009069">Movement Disorders</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010146">Pain</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010523">Peripheral Nervous System Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D054198">Precursor Cell Lymphoblastic Leukemia-Lymphoma</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012021">Reflex, Abnormal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011984">Sensory Receptor Cells</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013577">Syndrome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014034">Toes</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000293">injuries</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <NumberOfReferences>14</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1989</Year>
                <Month>1</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1989</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1989</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2559449</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">16135911</PMID>
        <DateCreated>
            <Year>2005</Year>
            <Month>09</Month>
            <Day>01</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2006</Year>
            <Month>03</Month>
            <Day>06</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0269-9370</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>19</Volume>
                    <Issue>14</Issue>
                    <PubDate>
                        <Year>2005</Year>
                        <Month>Sep</Month>
                        <Day>23</Day>
                    </PubDate>
                </JournalIssue>
                <Title>AIDS (London, England)</Title>
                <ISOAbbreviation>AIDS</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Bradycardia-tachycardia syndrome induced by lopinavir-ritonavir in a patient with AIDS.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1547-8</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Yotsumoto</LastName>
                    <ForeName>Mihoko</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kitano</LastName>
                    <ForeName>Kiyoshi</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Saito</LastName>
                    <ForeName>Hiroshi</ForeName>
                    <Initials>H</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016422">Letter</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>AIDS</MedlineTA>
            <NlmUniqueID>8710219</NlmUniqueID>
            <ISSNLinking>0269-9370</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017320">HIV Protease Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011744">Pyrimidinones</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>2494G1JF75</RegistryNumber>
                <NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>O3J8G9O825</RegistryNumber>
                <NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CitationSubset>X</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000163">Acquired Immunodeficiency Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019380">Anti-HIV Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001919">Bradycardia</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004338">Drug Combinations</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004417">Dyspnea</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004562">Electrocardiography</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017320">HIV Protease Inhibitors</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D061466">Lopinavir</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011744">Pyrimidinones</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019438">Ritonavir</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013577">Syndrome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013610">Tachycardia</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2005</Year>
                <Month>9</Month>
                <Day>2</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2006</Year>
                <Month>3</Month>
                <Day>7</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2005</Year>
                <Month>9</Month>
                <Day>2</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">00002030-200509230-00016</ArticleId>
            <ArticleId IdType="pubmed">16135911</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">2775019</PMID>
        <DateCreated>
            <Year>1989</Year>
            <Month>10</Month>
            <Day>12</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1989</Year>
            <Month>10</Month>
            <Day>12</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0045-0421</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>34</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>1989</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Australian dental journal</Title>
                <ISOAbbreviation>Aust Dent J</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Fatal subarachnoid haemorrhage associated with dental local anaesthesia.</ArticleTitle>
            <Pagination>
                <MedlinePgn>323-5</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>A case is described of sudden death occurring after the use of a noradrenaline-containing local anaesthetic. Autopsy revealed a massive subarachnoid haemorrhage following a ruptured cerebral aneurysm. The noradrenaline in the local anaesthetic is thought to be an important factor in the cause of the rupture. It is recommended that preparations containing 1:25,000 noradrenaline not be used.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Okada</LastName>
                    <ForeName>Y</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Suzuki</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ishiyama</LastName>
                    <ForeName>I</ForeName>
                    <Initials>I</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>AUSTRALIA</Country>
            <MedlineTA>Aust Dent J</MedlineTA>
            <NlmUniqueID>0370612</NlmUniqueID>
            <ISSNLinking>0045-0421</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000779">Anesthetics, Local</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014662">Vasoconstrictor Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>X4W3ENH1CV</RegistryNumber>
                <NameOfSubstance UI="D009638">Norepinephrine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>D</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000766">Anesthesia, Dental</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000779">Anesthetics, Local</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006973">Hypertension</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009638">Norepinephrine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013345">Subarachnoid Hemorrhage</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014081">Tooth Extraction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014662">Vasoconstrictor Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1989</Year>
                <Month>8</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1989</Year>
                <Month>8</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1989</Year>
                <Month>8</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2775019</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19339306</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>05</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>07</Month>
            <Day>08</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>09</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1460-2083</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>18</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Jun</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Human molecular genetics</Title>
                <ISOAbbreviation>Hum. Mol. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Loss of cone photoreceptors caused by chromophore depletion is partially prevented by the artificial chromophore pro-drug, 9-cis-retinyl acetate.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2277-87</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1093/hmg/ddp163</ELocationID>
            <Abstract>
                <AbstractText>Inactivating mutations in the retinoid isomerase (RPE65) or lecithin:retinol acyltransferase (LRAT) genes cause Leber congenital amaurosis (LCA), a severe visual impairment in humans. Both enzymes participate in the retinoid (visual) cycle, the enzymatic pathway that continuously generates 11-cis-retinal, the chromophore of visual pigments in rod and cone photoreceptor cells needed for vision. We investigated human RPE65-LCA patients and mice with visual cycle abnormalities to determine the impact of chronic chromophore deprivation on cones. Young patients with RPE65 mutations showed foveal cone loss along with shortened inner and outer segments of remaining cones; cone cell loss also was dramatic in young mice lacking Rpe65 or Lrat gene function. To selectively evaluate cone pathophysiology, we eliminated the rod contribution to electroretinographic (ERG) responses by generating double knockout mice lacking Lrat or Rpe65 together with an inactivated rod-specific G protein transducin gene (Gnat1-/-). Cone ERG responses were absent in Gnat1-/-Lrat-/- mice which also showed progressive degeneration of cones. Cone ERG responses in Gnat1-/-Rpe65-/- mice were markedly reduced and declined over weeks. Treatment of these mice with the artificial chromophore pro-drug, 9-cis-retinyl acetate, partially protected inferior retinal cones as evidenced by improved ERGs and retinal histochemistry. Gnat1-/- mice chronically treated with retinylamine, a selective inhibitor of RPE65, also showed a decline in the number of cones that was ameliorated by 9-cis-retinyl acetate. These results suggest that chronic lack of chromophore leads to progressive loss of cones in mice and humans. Therapy for LCA patients should be geared toward early adequate delivery of chromophore to cone photoreceptors.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Maeda</LastName>
                    <ForeName>Tadao</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology, School of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106-4965, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cideciyan</LastName>
                    <ForeName>Artur V</ForeName>
                    <Initials>AV</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Maeda</LastName>
                    <ForeName>Akiko</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Golczak</LastName>
                    <ForeName>Marcin</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Aleman</LastName>
                    <ForeName>Tomas S</ForeName>
                    <Initials>TS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jacobson</LastName>
                    <ForeName>Samuel G</ForeName>
                    <Initials>SG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Palczewski</LastName>
                    <ForeName>Krzysztof</ForeName>
                    <Initials>K</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>EY017280</GrantID>
                    <Acronym>EY</Acronym>
                    <Agency>NEI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>EY09339</GrantID>
                    <Acronym>EY</Acronym>
                    <Agency>NEI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>EY13203</GrantID>
                    <Acronym>EY</Acronym>
                    <Agency>NEI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>K08EY019031</GrantID>
                    <Acronym>EY</Acronym>
                    <Agency>NEI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P30 EY011373</GrantID>
                    <Acronym>EY</Acronym>
                    <Agency>NEI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P30 EY011373-139005</GrantID>
                    <Acronym>EY</Acronym>
                    <Agency>NEI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P30 EY11373</GrantID>
                    <Acronym>EY</Acronym>
                    <Agency>NEI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 EY009339</GrantID>
                    <Acronym>EY</Acronym>
                    <Agency>NEI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 EY009339-20</GrantID>
                    <Acronym>EY</Acronym>
                    <Agency>NEI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2009</Year>
                <Month>04</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Hum Mol Genet</MedlineTA>
            <NlmUniqueID>9208958</NlmUniqueID>
            <ISSNLinking>0964-6906</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005136">Eye Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D044385">GTP-Binding Protein alpha Subunits</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C488949">Gnat1 protein, mouse</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011355">Prodrugs</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>11103-57-4</RegistryNumber>
                <NameOfSubstance UI="D014801">Vitamin A</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>3LE3D9D6OY</RegistryNumber>
                <NameOfSubstance UI="C009166">retinol acetate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.-</RegistryNumber>
                <NameOfSubstance UI="C498954">Lrba protein, mouse</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.1.1.64</RegistryNumber>
                <NameOfSubstance UI="C052758">retinoid isomerohydrolase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.6.1.-</RegistryNumber>
                <NameOfSubstance UI="D015293">Transducin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 5.2.-</RegistryNumber>
                <NameOfSubstance UI="D019745">cis-trans-Isomerases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>RR725D715M</RegistryNumber>
                <NameOfSubstance UI="D012172">Retinaldehyde</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochemistry. 2005 Sep 6;44(35):11715-21</RefSource>
                <PMID Version="1">16128572</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8162-7</RefSource>
                <PMID Version="1">15917330</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4320-7</RefSource>
                <PMID Version="1">16249514</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13913-8</RefSource>
                <PMID Version="1">11095744</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS Med. 2005 Nov;2(11):e333</RefSource>
                <PMID Version="1">16250670</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Ther. 2005 Dec;12(6):1072-82</RefSource>
                <PMID Version="1">16226919</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2005 Dec 23;280(51):42263-73</RefSource>
                <PMID Version="1">16216874</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Invest Ophthalmol Vis Sci. 2006 Mar;47(3):1177-84</RefSource>
                <PMID Version="1">16505056</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Opt Express. 2008 Jul 21;16(15):11083-94</RefSource>
                <PMID Version="1">18648422</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Prog Retin Eye Res. 2008 Jul;27(4):391-419</RefSource>
                <PMID Version="1">18632300</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Opt Express. 2008 Sep 15;16(19):15149-69</RefSource>
                <PMID Version="1">18795054</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):15112-7</RefSource>
                <PMID Version="1">18809924</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4573-7</RefSource>
                <PMID Version="1">18539930</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Opt Express. 2008 Oct 13;16(21):16410-22</RefSource>
                <PMID Version="1">18852747</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Invest Ophthalmol Vis Sci. 2009 Jan;50(1):322-33</RefSource>
                <PMID Version="1">18708622</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Ther. 2009 Mar;17(3):516-23</RefSource>
                <PMID Version="1">19107120</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Mol Genet. 2009 Apr 1;18(7):1266-75</RefSource>
                <PMID Version="1">19147682</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Gene Ther. 2008 Oct;19(10):979-90</RefSource>
                <PMID Version="1">18774912</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Invest Ophthalmol Vis Sci. 2009 May;50(5):2368-75</RefSource>
                <PMID Version="1">19117922</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2009 May 29;284(22):15173-83</RefSource>
                <PMID Version="1">19304658</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Pharmacol. 2006 Oct;70(4):1220-9</RefSource>
                <PMID Version="1">16837623</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Invest Ophthalmol Vis Sci. 2006 Oct;47(10):4540-6</RefSource>
                <PMID Version="1">17003450</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS Med. 2006 Oct;3(10):e347</RefSource>
                <PMID Version="1">17032058</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Annu Rev Pharmacol Toxicol. 2007;47:469-512</RefSource>
                <PMID Version="1">16968212</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Adv Exp Med Biol. 2006;572:101-7</RefSource>
                <PMID Version="1">17249562</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Invest Ophthalmol Vis Sci. 2007 Feb;48(2):534-42</RefSource>
                <PMID Version="1">17251447</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2007 Sep 18;104(38):15123-8</RefSource>
                <PMID Version="1">17848510</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Neurosci. 2007 Oct;26(7):1940-9</RefSource>
                <PMID Version="1">17868371</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Ophthalmol. 2007 Dec;144(6):791-811</RefSource>
                <PMID Version="1">17964524</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19565-70</RefSource>
                <PMID Version="1">18048336</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Mol Genet. 2008 Jan 15;17(2):281-92</RefSource>
                <PMID Version="1">17933883</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2008 Apr 11;283(15):9543-54</RefSource>
                <PMID Version="1">18195010</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Neurosci. 2008 Apr 9;28(15):4008-14</RefSource>
                <PMID Version="1">18400900</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2008 May 22;358(21):2240-8</RefSource>
                <PMID Version="1">18441370</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2008 May 22;358(21):2231-9</RefSource>
                <PMID Version="1">18441371</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Invest Ophthalmol Vis Sci. 2008 Jun;49(6):2384-9</RefSource>
                <PMID Version="1">18296659</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neuron. 1999 Nov;24(3):541-53</RefSource>
                <PMID Version="1">10595508</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8623-8</RefSource>
                <PMID Version="1">10869443</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2001 May;28(1):92-5</RefSource>
                <PMID Version="1">11326284</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2002 May 24;277(21):19173-82</RefSource>
                <PMID Version="1">11897783</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neuron. 2002 Sep 26;36(1):69-80</RefSource>
                <PMID Version="1">12367507</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Mol Genet. 2003 May 1;12(9):1073-8</RefSource>
                <PMID Version="1">12700176</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13662-7</RefSource>
                <PMID Version="1">14578454</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Cell Biol. 2004 Feb 2;164(3):373-83</RefSource>
                <PMID Version="1">14745001</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2004 Mar 12;279(11):10422-32</RefSource>
                <PMID Version="1">14684738</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Invest Ophthalmol Vis Sci. 2004 Apr;45(4):1259-71</RefSource>
                <PMID Version="1">15037595</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Invest Ophthalmol Vis Sci. 1998 Nov;39(12):2405-16</RefSource>
                <PMID Version="1">9804149</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Vis. 1998 Oct 30;4:23</RefSource>
                <PMID Version="1">9808841</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 1998 Dec;20(4):344-51</RefSource>
                <PMID Version="1">9843205</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Invest Ophthalmol Vis Sci. 2005 Apr;46(4):1473-9</RefSource>
                <PMID Version="1">15790918</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):6177-82</RefSource>
                <PMID Version="1">15837919</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2005 May 13;280(19):18822-32</RefSource>
                <PMID Version="1">15755727</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Invest Ophthalmol Vis Sci. 2005 Oct;46(10):3876-82</RefSource>
                <PMID Version="1">16186377</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D048868">Adaptor Proteins, Signal Transducing</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002352">Carrier Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005136">Eye Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D044385">GTP-Binding Protein alpha Subunits</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D029242">Optic Atrophy, Hereditary, Leber</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011355">Prodrugs</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017949">Retinal Cone Photoreceptor Cells</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012172">Retinaldehyde</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000172">deficiency</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015293">Transducin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014801">Vitamin A</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019745">cis-trans-Isomerases</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC2685761</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2009</Year>
                <Month>4</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>4</Month>
                <Day>3</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>4</Month>
                <Day>3</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>7</Month>
                <Day>9</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ddp163</ArticleId>
            <ArticleId IdType="doi">10.1093/hmg/ddp163</ArticleId>
            <ArticleId IdType="pubmed">19339306</ArticleId>
            <ArticleId IdType="pmc">PMC2685761</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">24584071</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>04</Month>
            <Day>09</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>05</Month>
            <Day>19</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2015</Year>
            <Month>03</Month>
            <Day>12</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1546-1718</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>46</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nature genetics</Title>
                <ISOAbbreviation>Nat. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Loss-of-function mutations in SLC30A8 protect against type 2 diabetes.</ArticleTitle>
            <Pagination>
                <MedlinePgn>357-63</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/ng.2915</ELocationID>
            <Abstract>
                <AbstractText>Loss-of-function mutations protective against human disease provide in vivo validation of therapeutic targets, but none have yet been described for type 2 diabetes (T2D). Through sequencing or genotyping of ~150,000 individuals across 5 ancestry groups, we identified 12 rare protein-truncating variants in SLC30A8, which encodes an islet zinc transporter (ZnT8) and harbors a common variant (p.Trp325Arg) associated with T2D risk and glucose and proinsulin levels. Collectively, carriers of protein-truncating variants had 65% reduced T2D risk (P = 1.7  10(-6)), and non-diabetic Icelandic carriers of a frameshift variant (p.Lys34Serfs*50) demonstrated reduced glucose levels (-0.17 s.d., P = 4.6  10(-4)). The two most common protein-truncating variants (p.Arg138* and p.Lys34Serfs*50) individually associate with T2D protection and encode unstable ZnT8 proteins. Previous functional study of SLC30A8 suggested that reduced zinc transport increases T2D risk, and phenotypic heterogeneity was observed in mouse Slc30a8 knockouts. In contrast, loss-of-function mutations in humans provide strong evidence that SLC30A8 haploinsufficiency protects against T2D, suggesting ZnT8 inhibition as a therapeutic strategy in T2D prevention.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Flannick</LastName>
                    <ForeName>Jason</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA. [2] Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts, USA. [3] Diabetes Unit, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Thorleifsson</LastName>
                    <ForeName>Gudmar</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Beer</LastName>
                    <ForeName>Nicola L</ForeName>
                    <Initials>NL</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA. [2] Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jacobs</LastName>
                    <ForeName>Suzanne B R</ForeName>
                    <Initials>SB</Initials>
                    <Identifier Source="ORCID">0000000281031700</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Grarup</LastName>
                    <ForeName>Niels</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Burtt</LastName>
                    <ForeName>Nol P</ForeName>
                    <Initials>NP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mahajan</LastName>
                    <ForeName>Anubha</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fuchsberger</LastName>
                    <ForeName>Christian</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Statistical Genetics, Department of Biostatistics, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Atzmon</LastName>
                    <ForeName>Gil</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA. [2] Department of Genetics, Albert Einstein College of Medicine, Bronx, New York, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Benediktsson</LastName>
                    <ForeName>Rafn</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Endocrinology and Metabolism, Landspitali University Hospital, Reykjavik, Iceland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Blangero</LastName>
                    <ForeName>John</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Genetics, Texas Biomedical Research Institute, San Antonio, Texas, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bowden</LastName>
                    <ForeName>Don W</ForeName>
                    <Initials>DW</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Center for Genomics and Personalized Medicine Research, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA. [2] Center for Diabetes Research, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA. [3] Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA. [4] Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brandslund</LastName>
                    <ForeName>Ivan</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Department of Clinical Biochemistry, Vejle Hospital, Vejle, Denmark. [2] Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brosnan</LastName>
                    <ForeName>Julia</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cardiovascular &amp; Metabolic Diseases Research Unit, Pfizer, Inc., Cambridge, Massachusetts, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Burslem</LastName>
                    <ForeName>Frank</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cardiovascular and Metabolic Diseases Practice, Prescient Life Sciences, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chambers</LastName>
                    <ForeName>John</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Department of Epidemiology and Biostatistics, Imperial College London, London, UK. [2] Imperial College Healthcare National Health Service (NHS) Trust, London, UK. [3] Ealing Hospital NHS Trust, Middlesex, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cho</LastName>
                    <ForeName>Yoon Shin</ForeName>
                    <Initials>YS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biomedical Science, Hallym University, Chuncheon, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Christensen</LastName>
                    <ForeName>Cramer</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine and Endocrinology, Vejle Hospital, Vejle, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Douglas</LastName>
                    <ForeName>Desire A</ForeName>
                    <Initials>DA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Unit of Diabetes and Celiac Diseases, Department of Clinical Sciences, Lund University, Malm, Sweden.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Duggirala</LastName>
                    <ForeName>Ravindranath</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Genetics, Texas Biomedical Research Institute, San Antonio, Texas, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dymek</LastName>
                    <ForeName>Zachary</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Farjoun</LastName>
                    <ForeName>Yossi</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fennell</LastName>
                    <ForeName>Timothy</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fontanillas</LastName>
                    <ForeName>Pierre</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Forsn</LastName>
                    <ForeName>Tom</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Department of General Practice and Primary Health Care, University of Helsinki, Helsinki, Finland. [2] Diabetes Care Unit, Vaasa Health Care Centre, Vaasa, Finland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gabriel</LastName>
                    <ForeName>Stacey</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Glaser</LastName>
                    <ForeName>Benjamin</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Endocrinology and Metabolism Service, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. [2] Israel Diabetes Research Group (IDRG), Holon, Israel.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gudbjartsson</LastName>
                    <ForeName>Daniel F</ForeName>
                    <Initials>DF</Initials>
                    <AffiliationInfo>
                        <Affiliation>deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hanis</LastName>
                    <ForeName>Craig</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Human Genetics Center, University of Texas Health Science Center at Houston, Houston, Texas, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hansen</LastName>
                    <ForeName>Torben</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. [2] Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hreidarsson</LastName>
                    <ForeName>Astradur B</ForeName>
                    <Initials>AB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Endocrinology and Metabolism, Landspitali University Hospital, Reykjavik, Iceland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hveem</LastName>
                    <ForeName>Kristian</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Public Health, Faculty of Medicine, Norwegian University of Science and Technology, Levanger, Norway.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ingelsson</LastName>
                    <ForeName>Erik</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK. [2] Molecular Epidemiology and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Isomaa</LastName>
                    <ForeName>Bo</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Folkhalsan Research Centre, Helsinki, Finland. [2] Department of Social Services and Health Care, Jakobstad, Finland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Johansson</LastName>
                    <ForeName>Stefan</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] KG Jebsen Center for Diabetes Research, Department of Clinical Science, University of Bergen, Bergen, Norway. [2] Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway. [3] Department of Biomedicine, University of Bergen, Bergen, Norway.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jrgensen</LastName>
                    <ForeName>Torben</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Research Centre for Prevention and Health, Glostrup University Hospital, Glostrup, Denmark. [2] Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. [3] Faculty of Medicine, University of Aalborg, Aalborg, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jrgensen</LastName>
                    <ForeName>Marit Eika</ForeName>
                    <Initials>ME</Initials>
                    <AffiliationInfo>
                        <Affiliation>Steno Diabetes Center, Gentofte, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kathiresan</LastName>
                    <ForeName>Sekar</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA. [2] Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts, USA. [3] Cardiovascular Research Center, Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts, USA. [4] Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kong</LastName>
                    <ForeName>Augustine</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kooner</LastName>
                    <ForeName>Jaspal</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Imperial College Healthcare National Health Service (NHS) Trust, London, UK. [2] Ealing Hospital NHS Trust, Middlesex, UK. [3] National Heart and Lung Institute (NHLI), Imperial College London, Hammersmith Hospital, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kravic</LastName>
                    <ForeName>Jasmina</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Sciences, Diabetes and Endocrinology, Lund University Diabetes Centre, Malm, Sweden.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Laakso</LastName>
                    <ForeName>Markku</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, University of Eastern Finland, Kuopio Campus and Kuopio University Hospital, Kuopio, Finland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Jong-Young</ForeName>
                    <Initials>JY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Genome Science, Korea National Institute of Health, Osong Health Technology, Chungcheongbuk-do, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lind</LastName>
                    <ForeName>Lars</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Sciences, Uppsala University, Uppsala, Sweden.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lindgren</LastName>
                    <ForeName>Cecilia M</ForeName>
                    <Initials>CM</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA. [2] Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Linneberg</LastName>
                    <ForeName>Allan</ForeName>
                    <Initials>A</Initials>
                    <Identifier Source="ORCID">0000000209940184</Identifier>
                    <AffiliationInfo>
                        <Affiliation>1] Research Centre for Prevention and Health, Glostrup University Hospital, Glostrup, Denmark. [2] Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. [3] Department of Clinical Experimental Research, Glostrup University Hospital, Glostrup, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Masson</LastName>
                    <ForeName>Gisli</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Meitinger</LastName>
                    <ForeName>Thomas</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Human Genetics, Technical University Munich, Munich, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mohlke</LastName>
                    <ForeName>Karen L</ForeName>
                    <Initials>KL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Genetics, University of North Carolina, Chapel Hill, North Carolina, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Molven</LastName>
                    <ForeName>Anders</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] KG Jebsen Center for Diabetes Research, Department of Clinical Science, University of Bergen, Bergen, Norway. [2] Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway. [3] Department of Pathology, Haukeland University Hospital, Bergen, Norway.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Morris</LastName>
                    <ForeName>Andrew P</ForeName>
                    <Initials>AP</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK. [2] Department of Biostatistics, University of Liverpool, Liverpool, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Potluri</LastName>
                    <ForeName>Shobha</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Applied Quantitative Genotherapeutics, Pfizer, Inc., South San Francisco, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rauramaa</LastName>
                    <ForeName>Rainer</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Kuopio Research Institute of Exercise Medicine, Kuopio, Finland. [2] Department of Clinical Physiology and Nuclear Medicine, Kuopio University Hospital, Kuopio, Finland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ribel-Madsen</LastName>
                    <ForeName>Rasmus</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Richard</LastName>
                    <ForeName>Ann-Marie</ForeName>
                    <Initials>AM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cardiovascular &amp; Metabolic Diseases Research Unit, Pfizer, Inc., Cambridge, Massachusetts, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rolph</LastName>
                    <ForeName>Tim</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cardiovascular &amp; Metabolic Diseases Research Unit, Pfizer, Inc., Cambridge, Massachusetts, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Salomaa</LastName>
                    <ForeName>Veikko</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>National Institute for Health and Welfare (THL), Helsinki, Finland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Segr</LastName>
                    <ForeName>Ayellet V</ForeName>
                    <Initials>AV</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA. [2] Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Skrstrand</LastName>
                    <ForeName>Hanna</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Unit of Diabetes and Celiac Diseases, Department of Clinical Sciences, Lund University, Malm, Sweden.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Steinthorsdottir</LastName>
                    <ForeName>Valgerdur</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stringham</LastName>
                    <ForeName>Heather M</ForeName>
                    <Initials>HM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Statistical Genetics, Department of Biostatistics, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sulem</LastName>
                    <ForeName>Patrick</ForeName>
                    <Initials>P</Initials>
                    <Identifier Source="ORCID">0000000171236123</Identifier>
                    <AffiliationInfo>
                        <Affiliation>deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tai</LastName>
                    <ForeName>E Shyong</ForeName>
                    <Initials>ES</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Saw Swee Hock School of Public Health, National University of Singapore, National University Health System, Singapore. [2] Department of Medicine, National University of Singapore, National University Health System, Singapore. [3] Duke-National University of Singapore Graduate Medical School, Singapore.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Teo</LastName>
                    <ForeName>Yik Ying</ForeName>
                    <Initials>YY</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Saw Swee Hock School of Public Health, National University of Singapore, National University Health System, Singapore. [2] Centre for Molecular Epidemiology, National University of Singapore, Singapore. [3] Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore. [4] Graduate School for Integrative Science and Engineering, National University of Singapore, Singapore. [5] Department of Statistics and Applied Probability, National University of Singapore, Singapore.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Teslovich</LastName>
                    <ForeName>Tanya</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Statistical Genetics, Department of Biostatistics, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Thorsteinsdottir</LastName>
                    <ForeName>Unnur</ForeName>
                    <Initials>U</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] deCODE Genetics/Amgen, Inc., Reykjavik, Iceland. [2] Faculty of Medicine, University of Iceland, Reykjavk, Iceland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Trimmer</LastName>
                    <ForeName>Jeff K</ForeName>
                    <Initials>JK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cardiovascular &amp; Metabolic Diseases Research Unit, Pfizer, Inc., Cambridge, Massachusetts, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tuomi</LastName>
                    <ForeName>Tiinamaija</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Department of General Practice and Primary Health Care, University of Helsinki, Helsinki, Finland. [2] Folkhalsan Research Centre, Helsinki, Finland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tuomilehto</LastName>
                    <ForeName>Jaakko</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Centre for Vascular Prevention, Danube-University Krems, Krems, Austria. [2] Diabetes Prevention Unit, National Institute for Health and Welfare, Helsinki, Finland. [3] Diabetes Research Group, King Abdulaziz University, Jeddah, Saudi Arabia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vaziri-Sani</LastName>
                    <ForeName>Fariba</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Unit of Diabetes and Celiac Diseases, Department of Clinical Sciences, Lund University, Malm, Sweden.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Voight</LastName>
                    <ForeName>Benjamin F</ForeName>
                    <Initials>BF</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA. [2] Department of Pharmacology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA. [3] Department of Genetics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wilson</LastName>
                    <ForeName>James G</ForeName>
                    <Initials>JG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, Mississippi, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Boehnke</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Statistical Genetics, Department of Biostatistics, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McCarthy</LastName>
                    <ForeName>Mark I</ForeName>
                    <Initials>MI</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK. [2] Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK. [3] Oxford National Institute for Health Research (NIHR) Biomedical Research Centre, Churchill Hospital, Oxford, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Njlstad</LastName>
                    <ForeName>Pl R</ForeName>
                    <Initials>PR</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA. [2] KG Jebsen Center for Diabetes Research, Department of Clinical Science, University of Bergen, Bergen, Norway. [3] Department of Pediatrics, Haukeland University Hospital, Bergen, Norway.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pedersen</LastName>
                    <ForeName>Oluf</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>Go-T2D Consortium</CollectiveName>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>T2D-GENES Consortium</CollectiveName>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Groop</LastName>
                    <ForeName>Leif</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Department of Clinical Sciences, Diabetes and Endocrinology, Lund University Diabetes Centre, Malm, Sweden. [2] Finnish Institute for Molecular Medicine (FIMM), Helsinki University, Helsinki, Finland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cox</LastName>
                    <ForeName>David R</ForeName>
                    <Initials>DR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Applied Quantitative Genotherapeutics, Pfizer, Inc., South San Francisco, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stefansson</LastName>
                    <ForeName>Kari</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] deCODE Genetics/Amgen, Inc., Reykjavik, Iceland. [2] Faculty of Medicine, University of Iceland, Reykjavk, Iceland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Altshuler</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA. [2] Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts, USA. [3] Diabetes Unit, Massachusetts General Hospital, Boston, Massachusetts, USA. [4] Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts, USA. [5] Cardiovascular Research Center, Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts, USA. [6] Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA. [7] Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>090532</GrantID>
                    <Agency>Wellcome Trust</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>098017</GrantID>
                    <Agency>Wellcome Trust</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>098381</GrantID>
                    <Agency>Wellcome Trust</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>5U01DK085526</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>DK088389</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>NF-SI-0611-10099</GrantID>
                    <Agency>Department of Health</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 DK072193</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 DK093757</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R13 CA124293</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>RC2 DK088389</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01 DK062370</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01 DK085501</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01 DK085524</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01 DK085524</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01 DK085526</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01 DK085545</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01 DK085584</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U54 HG003067</GrantID>
                    <Acronym>HG</Acronym>
                    <Agency>NHGRI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U54HG003067</GrantID>
                    <Acronym>HG</Acronym>
                    <Agency>NHGRI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>03</Month>
                <Day>02</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Nat Genet</MedlineTA>
            <NlmUniqueID>9216904</NlmUniqueID>
            <ISSNLinking>1061-4036</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D027682">Cation Transport Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C492522">SLC30A8 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9035-68-1</RegistryNumber>
                <NameOfSubstance UI="D011384">Proinsulin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2010 Feb;42(2):105-16</RefSource>
                <PMID Version="1">20081858</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2010 Feb;42(2):142-8</RefSource>
                <PMID Version="1">20081857</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Diab Rep. 2010 Dec;10(6):452-66</RefSource>
                <PMID Version="1">20878272</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Islets. 2010 Jan-Feb;2(1):49-50</RefSource>
                <PMID Version="1">21099294</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Diabetes. 2011 Oct;60(10):2624-34</RefSource>
                <PMID Version="1">21873549</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2012 Mar;44(3):243-6</RefSource>
                <PMID Version="1">22306651</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Physiol Endocrinol Metab. 2012 May 15;302(9):E1084-96</RefSource>
                <PMID Version="1">22338079</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2012;7(7):e40972</RefSource>
                <PMID Version="1">22829903</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2012 Sep;44(9):981-90</RefSource>
                <PMID Version="1">22885922</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2012 Dec;44(12):1326-9</RefSource>
                <PMID Version="1">23104005</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>JAMA. 2012 Dec 19;308(23):2497-506</RefSource>
                <PMID Version="1">23128163</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Diabetes Res. 2013;2013:906590</RefSource>
                <PMID Version="1">23710470</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Drug Discov. 2013 Aug;12(8):581-94</RefSource>
                <PMID Version="1">23868113</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Invest. 2013 Oct;123(10):4513-24</RefSource>
                <PMID Version="1">24051378</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genet Epidemiol. 2011 May;35(4):236-46</RefSource>
                <PMID Version="1">21308769</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Diabetologia. 2010 Aug;53(8):1656-68</RefSource>
                <PMID Version="1">20424817</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2009 Sep 1;106(35):14872-7</RefSource>
                <PMID Version="1">19706465</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Diabetes. 2009 Sep;58(9):2070-83</RefSource>
                <PMID Version="1">19542200</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12706-11</RefSource>
                <PMID Version="1">15314237</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Issues Mol Biol. 2001 Jul;3(3):57-65</RefSource>
                <PMID Version="1">11488412</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Diabetes. 2004 Sep;53(9):2330-7</RefSource>
                <PMID Version="1">15331542</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2005 Feb;37(2):161-5</RefSource>
                <PMID Version="1">15654334</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Methods Enzymol. 2005;399:249-66</RefSource>
                <PMID Version="1">16338361</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Cell Sci. 2006 Oct 15;119(Pt 20):4199-206</RefSource>
                <PMID Version="1">16984975</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2007 Feb 22;445(7130):881-5</RefSource>
                <PMID Version="1">17293876</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 2009 Apr 17;324(5925):387-9</RefSource>
                <PMID Version="1">19264985</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem J. 2009 Aug 1;421(3):371-6</RefSource>
                <PMID Version="1">19450229</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Nat Genet. 2014 Apr;46(4):323-4</RefSource>
                <PMID Version="1">24675520</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Am J Manag Care. 2014 Mar;20(4 Spec No.):E7</RefSource>
                <PMID Version="1">25618503</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Clin Genet. 2014 Aug;86(2):121-2</RefSource>
                <PMID Version="1">24766504</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001483">Base Sequence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001786">Blood Glucose</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D027682">Cation Transport Proteins</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003924">Diabetes Mellitus, Type 2</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D056726">Genetic Association Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005838">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017136">Ion Transport</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008969">Molecular Sequence Data</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020125">Mutation, Missense</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011384">Proinsulin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017422">Sequence Analysis, DNA</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">NIHMS582091</OtherID>
        <OtherID Source="NLM">PMC4051628</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>9</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ng.2915</ArticleId>
            <ArticleId IdType="doi">10.1038/ng.2915</ArticleId>
            <ArticleId IdType="pubmed">24584071</ArticleId>
            <ArticleId IdType="pmc">PMC4051628</ArticleId>
            <ArticleId IdType="mid">NIHMS582091</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">3935601</PMID>
        <DateCreated>
            <Year>1986</Year>
            <Month>01</Month>
            <Day>29</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1986</Year>
            <Month>01</Month>
            <Day>29</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0017-8748</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>25</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>1985</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Headache</Title>
                <ISOAbbreviation>Headache</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Lithium-triggered chronic cluster headache.</ArticleTitle>
            <Pagination>
                <MedlinePgn>394-5</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Brainin</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Eisenstdter</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Headache</MedlineTA>
            <NlmUniqueID>2985091R</NlmUniqueID>
            <ISSNLinking>0017-8748</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>2BMD2GNA4V</RegistryNumber>
                <NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9FN79X2M3F</RegistryNumber>
                <NameOfSubstance UI="D008094">Lithium</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002908">Chronic Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003027">Cluster Headache</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008094">Lithium</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016651">Lithium Carbonate</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014653">Vascular Headaches</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1985</Year>
                <Month>10</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1985</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1985</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3935601</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">17881535</PMID>
        <DateCreated>
            <Year>2007</Year>
            <Month>09</Month>
            <Day>20</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2007</Year>
            <Month>10</Month>
            <Day>11</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2007</Year>
            <Month>12</Month>
            <Day>03</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1529-2401</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>27</Volume>
                    <Issue>38</Issue>
                    <PubDate>
                        <Year>2007</Year>
                        <Month>Sep</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title>
                <ISOAbbreviation>J. Neurosci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Chemical interactions between fibrosarcoma cancer cells and sensory neurons contribute to cancer pain.</ArticleTitle>
            <Pagination>
                <MedlinePgn>10289-98</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>In an experimental model of cancer pain, the hyperalgesia that occurs with osteolytic tumor growth is associated with the sensitization of nociceptors. We examined functional and molecular changes in small-diameter dorsal root ganglion (DRG) neurons to determine cellular mechanisms underlying this sensitization. The occurrence of a Ca2+ transient in response to either KCl (25 mM) or capsaicin (500 nM) increased in small neurons isolated from murine L3-L6 DRGs ipsilateral to fibrosarcoma cell tumors. The increased responses were associated with increased mRNA levels for the Ca2+ channel subunit alpha2delta1 and TRPV1 receptor. Pretreatment with gabapentin, an inhibitor of the alpha2delta1 subunit, blocked the increased response to KCl in vitro and the mechanical hyperalgesia in tumor-bearing mice in vivo. Similar increases in neuronal responsiveness occurred when DRG neurons from naive mice and fibrosarcoma cells were cocultured for 48 h. The CC chemokine ligand 2 (CCL2) may contribute to the tumor cell-induced sensitization because CCL2 immunoreactivity was present in tumors, high levels of CCL2 peptide were present in microperfusates from tumors, and treatment of DRG neurons in vitro with CCL2 increased the amount of mRNA for the alpha2delta1 subunit. Together, our data provide strong evidence that the chemical mediator CCL2 is released from tumor cells and evokes phenotypic changes in sensory neurons, including increases in voltage-gated Ca2+ channels that likely underlie the mechanical hyperalgesia in the fibrosarcoma cancer model. More broadly, this study provides a novel in vitro model to resolve the cellular and molecular mechanisms by which tumor cells drive functional changes in nociceptors.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Khasabova</LastName>
                    <ForeName>Iryna A</ForeName>
                    <Initials>IA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Diagnostic and Biological Sciences, University of Minnesota, Minneapolis, Minnesota 55455, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stucky</LastName>
                    <ForeName>Cheryl L</ForeName>
                    <Initials>CL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Harding-Rose</LastName>
                    <ForeName>Catherine</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Eikmeier</LastName>
                    <ForeName>Laura</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Beitz</LastName>
                    <ForeName>Alvin J</ForeName>
                    <Initials>AJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Coicou</LastName>
                    <ForeName>Lia G</ForeName>
                    <Initials>LG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hanson</LastName>
                    <ForeName>Amy E</ForeName>
                    <Initials>AE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Simone</LastName>
                    <ForeName>Donald A</ForeName>
                    <Initials>DA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Seybold</LastName>
                    <ForeName>Virginia S</ForeName>
                    <Initials>VS</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>CA084233</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>CA091007</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>DA11471</GrantID>
                    <Acronym>DA</Acronym>
                    <Agency>NIDA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>NS40538</GrantID>
                    <Acronym>NS</Acronym>
                    <Agency>NINDS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Neurosci</MedlineTA>
            <NlmUniqueID>8102140</NlmUniqueID>
            <ISSNLinking>0270-6474</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018920">Coculture Techniques</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005354">Fibrosarcoma</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008809">Mice, Inbred C3H</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009475">Neurons, Afferent</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010146">Pain</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010147">Pain Measurement</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014407">Tumor Cells, Cultured</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2007</Year>
                <Month>9</Month>
                <Day>21</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2007</Year>
                <Month>10</Month>
                <Day>12</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2007</Year>
                <Month>9</Month>
                <Day>21</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">27/38/10289</ArticleId>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.2851-07.2007</ArticleId>
            <ArticleId IdType="pubmed">17881535</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">24584070</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>03</Month>
            <Day>28</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>05</Month>
            <Day>19</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1546-1718</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>46</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nature genetics</Title>
                <ISOAbbreviation>Nat. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma.</ArticleTitle>
            <Pagination>
                <MedlinePgn>371-5</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/ng.2916</ELocationID>
            <Abstract>
                <AbstractText>The molecular mechanisms underlying angioimmunoblastic T cell lymphoma (AITL), a common type of mature T cell lymphoma of poor prognosis, are largely unknown. Here we report a frequent somatic mutation in RHOA (encoding p.Gly17Val) using exome and transcriptome sequencing of samples from individuals with AITL. Further examination of the RHOA mutation encoding p.Gly17Val in 239 lymphoma samples showed that the mutation was specific to T cell lymphoma and was absent from B cell lymphoma. We demonstrate that the RHOA mutation encoding p.Gly17Val, which was found in 53.3% (24 of 45) of the AITL cases examined, is oncogenic in nature using multiple molecular assays. Molecular modeling and docking simulations provided a structural basis for the loss of GTPase activity in the RHOA Gly17Val mutant. Our experimental data and modeling results suggest that the RHOA mutation encoding p.Gly17Val is a driver mutation in AITL. On the basis of these data and through integrated pathway analysis, we build a comprehensive signaling network for AITL oncogenesis.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Yoo</LastName>
                    <ForeName>Hae Yong</ForeName>
                    <Initials>HY</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea. [2] Samsung Biomedical Research Institute, Research Institute for Future Medicine, Samsung Medical Center, Seoul, Korea. [3].</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sung</LastName>
                    <ForeName>Min Kyung</ForeName>
                    <Initials>MK</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Korean Bioinformation Center (KOBIC), Korea Research Institute of Bioscience and Biotechnology, Daejeon, Korea. [2].</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Seung Ho</ForeName>
                    <Initials>SH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Sangok</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Ewha Research Center for Systems Biology (ERCSB), Ewha Womans University, Seoul, Korea. [2] Department of Life Science, Ewha Womans University, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Haeseung</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Ewha Research Center for Systems Biology (ERCSB), Ewha Womans University, Seoul, Korea. [2] Department of Life Science, Ewha Womans University, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Park</LastName>
                    <ForeName>Seongjin</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Korean Bioinformation Center (KOBIC), Korea Research Institute of Bioscience and Biotechnology, Daejeon, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Sang Cheol</ForeName>
                    <Initials>SC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Korean Bioinformation Center (KOBIC), Korea Research Institute of Bioscience and Biotechnology, Daejeon, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Byungwook</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Korean Bioinformation Center (KOBIC), Korea Research Institute of Bioscience and Biotechnology, Daejeon, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rho</LastName>
                    <ForeName>Kyoohyoung</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>DNA Link, Inc., Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Jong-Eun</ForeName>
                    <Initials>JE</Initials>
                    <AffiliationInfo>
                        <Affiliation>DNA Link, Inc., Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cho</LastName>
                    <ForeName>Kwang-Hwi</ForeName>
                    <Initials>KH</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Systems Biomedical Science, Soongsil University, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Wankyu</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Ewha Research Center for Systems Biology (ERCSB), Ewha Womans University, Seoul, Korea. [2] Department of Life Science, Ewha Womans University, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ju</LastName>
                    <ForeName>Hyunjung</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Samsung Biomedical Research Institute, Research Institute for Future Medicine, Samsung Medical Center, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Jaesang</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Ewha Research Center for Systems Biology (ERCSB), Ewha Womans University, Seoul, Korea. [2] Department of Life Science, Ewha Womans University, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Seok Jin</ForeName>
                    <Initials>SJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Samsung Biomedical Research Institute, Research Institute for Future Medicine, Samsung Medical Center, Seoul, Korea. [2] Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Won Seog</ForeName>
                    <Initials>WS</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Samsung Biomedical Research Institute, Research Institute for Future Medicine, Samsung Medical Center, Seoul, Korea. [2] Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Sanghyuk</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Ewha Research Center for Systems Biology (ERCSB), Ewha Womans University, Seoul, Korea. [2] Department of Life Science, Ewha Womans University, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ko</LastName>
                    <ForeName>Young Hyeh</ForeName>
                    <Initials>YH</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Samsung Biomedical Research Institute, Research Institute for Future Medicine, Samsung Medical Center, Seoul, Korea. [2] Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>SRA</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>SRP029591</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>03</Month>
                <Day>02</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Nat Genet</MedlineTA>
            <NlmUniqueID>9216904</NlmUniqueID>
            <ISSNLinking>1061-4036</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>124671-05-2</RegistryNumber>
                <NameOfSubstance UI="C066737">RHOA protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.6.5.2</RegistryNumber>
                <NameOfSubstance UI="D020742">rhoA GTP-Binding Protein</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Nat Genet. 2014 Apr;46(4):320-1</RefSource>
                <PMID Version="1">24675518</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001483">Base Sequence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D055028">Comparative Genomic Hybridization</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D059472">Exome</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D020868">Gene Silencing</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D059014">High-Throughput Nucleotide Sequencing</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016399">Lymphoma, T-Cell</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008954">Models, Biological</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D008958">Models, Molecular</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008969">Molecular Sequence Data</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020125">Mutation, Missense</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020641">Polymorphism, Single Nucleotide</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011485">Protein Binding</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017423">Sequence Analysis, RNA</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D059467">Transcriptome</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020742">rhoA GTP-Binding Protein</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>11</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ng.2916</ArticleId>
            <ArticleId IdType="doi">10.1038/ng.2916</ArticleId>
            <ArticleId IdType="pubmed">24584070</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">1607191</PMID>
        <DateCreated>
            <Year>1992</Year>
            <Month>07</Month>
            <Day>23</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1992</Year>
            <Month>07</Month>
            <Day>23</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0266-4348</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>68</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>1992</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Genitourinary medicine</Title>
                <ISOAbbreviation>Genitourin Med</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Lidocaine/prilocaine cream (EMLA(R)) versus infiltration anaesthesia: a comparison of the analgesic efficacy for punch biopsy and electrocoagulation of genital warts in men.</ArticleTitle>
            <Pagination>
                <MedlinePgn>162-5</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To compare analgesic efficacy and pain caused by administration of lidocaine/prilocaine cream (EMLA(R)) versus xylocaine 1% local infiltration for punch biopsy and electrocoagulation of genital warts in men.</AbstractText>
                <AbstractText Label="DESIGN" NlmCategory="METHODS">Open randomised comparative parallel-group study.</AbstractText>
                <AbstractText Label="SETTING" NlmCategory="METHODS">Department of Dermatovenereology, University Hospital Rotterdam/Dijkzigt, the Netherlands.</AbstractText>
                <AbstractText Label="PATIENTS" NlmCategory="METHODS">63 males with warts on the genital mucosa and/or perianal area.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">EMLA(R) cream (2.5-5 g) was applied during 13-45 minutes before surgery. Xylocaine 1% (0.1-4 ml) was infiltrated 0.5-4 minutes before surgery. Pain during administration and surgery was assessed by the patient on a verbal rating scale and on a visual analogue scale.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">EMLA(R) application was painless in all patients (n = 31) whereas xylocaine infiltration was slightly painful in 17/29 patients and moderately painful in 10/29 patients. EMLA(R) analgesia was satisfactory for 94% of biopsies and 62% of electrocoagulations. Xylocaine infiltration was satisfactory in all procedures.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">EMLA(R) application on the male genital mucosa is painless but it has a lower analgesic efficacy than xylocaine infiltration. However EMLA is a useful anaesthetic for taking biopsies in this area and may be used as premedication for local infiltration.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>vd Berg</LastName>
                    <ForeName>G M</ForeName>
                    <Initials>GM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Dermatovenereology, University Hospital Rotterdam/Dijkzigt, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lillieborg</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stolz</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016430">Clinical Trial</PublicationType>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>ENGLAND</Country>
            <MedlineTA>Genitourin Med</MedlineTA>
            <NlmUniqueID>8503853</NlmUniqueID>
            <ISSNLinking>0266-4348</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000779">Anesthetics, Local</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C036626">EMLA</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>046O35D44R</RegistryNumber>
                <NameOfSubstance UI="D011318">Prilocaine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>98PI200987</RegistryNumber>
                <NameOfSubstance UI="D008012">Lidocaine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Sex Transm Dis. 1990 Jul-Sep;17(3):130-2</RefSource>
                <PMID Version="1">2247802</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Annu Rev Public Health. 1988;9:123-60</RefSource>
                <PMID Version="1">3288229</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Acta Derm Venereol. 1989;69(4):362-5</RefSource>
                <PMID Version="1">2568066</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Obstet Gynaecol. 1989 Apr;96(4):497-9</RefSource>
                <PMID Version="1">2751968</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pain. 1976 Jun;2(2):175-84</RefSource>
                <PMID Version="1">1026900</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genitourin Med. 1987 Oct;63(5):316-9</RefSource>
                <PMID Version="1">3315960</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Adv Dermatol. 1990;5:75-91; discussion 92</RefSource>
                <PMID Version="1">2204380</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Obstet Gynecol. 1990 Feb;75(2):302-6</RefSource>
                <PMID Version="1">2405326</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Anesth Analg. 1988 Feb;67(2):115-23</RefSource>
                <PMID Version="1">3341564</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000772">Anesthesia, Local</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D000779">Anesthetics, Local</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001706">Biopsy</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004338">Drug Combinations</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D004564">Electrocoagulation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005832">Genital Diseases, Male</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000601">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D008012">Lidocaine</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010147">Pain Measurement</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D011318">Prilocaine</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014860">Warts</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000601">surgery</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC1194847</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1992</Year>
                <Month>6</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1992</Year>
                <Month>6</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1992</Year>
                <Month>6</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1607191</ArticleId>
            <ArticleId IdType="pmc">PMC1194847</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">15954974</PMID>
        <DateCreated>
            <Year>2005</Year>
            <Month>06</Month>
            <Day>15</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2005</Year>
            <Month>10</Month>
            <Day>13</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0001-5172</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>49</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2005</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Acta anaesthesiologica Scandinavica</Title>
                <ISOAbbreviation>Acta Anaesthesiol Scand</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Safety of mixture of morphine with ketamine for postoperative patient-controlled analgesia: an audit with 1026 patients.</ArticleTitle>
            <Pagination>
                <MedlinePgn>870-5</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Adding ketamine to morphine for patient-controlled analgesia (PCA) may be useful. However, data on this drug combination have been collected on small sample sizes. In order to evaluate the safety of the combination morphine- ketamine, we conducted a prospective study on a large patient population.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Patient-controlled analgesia was performed with 1026 patients using morphine and ketamine in a dose ratio of 1:1. All patients were treated in the ward. Prospectively collected data included incidence of complications and side-effects, verbal pain scores at rest and during mobilization (0 = no pain to 4 = very strong pain), consumption of morphine and ketamine and patient satisfaction (0 = very un-satisfied to 3 = very satisfied).</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The study included 462 women and 564 men who underwent, on average, 71.8 h (+/-56.1) of PCA. There were 698 orthopaedic, 160 abdominal, 96 thoracic, 20 vascular, 16 plastic, 15 neurosurgical, 11 urologic and 10 other surgical procedures. No complication was observed. Incidence of side-effects was: 1.2% respiratory depression, 23.5% nausea, 6.2% vivid dreams and/or hallucinations, 21.4% sedation and 10.3% pruritus. Reasons for discontinuing the PCA were side-effects (7.0%) and other (0.5%). Mean pain scores over the whole period were 0.44 (+/-0.54) at rest and 1.36 (+/-0.62) during mobilization. Mean satisfaction score was 2.52 (+/-0.69).</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Patient-controlled analgesia with morphine and ketamine is safe. It produces side-effects which, however, are infrequently a reason for discontinuing the regimen. It is also associated with low pain scores and high patient satisfaction.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sveticic</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Anesthesiology, Division of Pain Therapy, University of Bern, Inselspital, Switzerland. gorazd.sveticic@insel.ch</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Eichenberger</LastName>
                    <ForeName>U</ForeName>
                    <Initials>U</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Curatolo</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Denmark</Country>
            <MedlineTA>Acta Anaesthesiol Scand</MedlineTA>
            <NlmUniqueID>0370270</NlmUniqueID>
            <ISSNLinking>0001-5172</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000701">Analgesics, Opioid</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000778">Anesthetics, Dissociative</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>68-89-3</RegistryNumber>
                <NameOfSubstance UI="D004177">Dipyrone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>690G0D6V8H</RegistryNumber>
                <NameOfSubstance UI="D007649">Ketamine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>76I7G6D29C</RegistryNumber>
                <NameOfSubstance UI="D009020">Morphine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>YZI5105V0L</RegistryNumber>
                <NameOfSubstance UI="D020910">Ketorolac</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016058">Analgesia, Patient-Controlled</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000701">Analgesics, Opioid</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000778">Anesthetics, Dissociative</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004177">Dipyrone</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004338">Drug Combinations</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007649">Ketamine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020910">Ketorolac</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009020">Morphine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010147">Pain Measurement</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010149">Pain, Postoperative</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017060">Patient Satisfaction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2005</Year>
                <Month>6</Month>
                <Day>16</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2005</Year>
                <Month>10</Month>
                <Day>14</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2005</Year>
                <Month>6</Month>
                <Day>16</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">AAS740</ArticleId>
            <ArticleId IdType="doi">10.1111/j.1399-6576.2005.00740.x</ArticleId>
            <ArticleId IdType="pubmed">15954974</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">6429463</PMID>
        <DateCreated>
            <Year>1984</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1984</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0025-7753</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>82</Volume>
                    <Issue>18</Issue>
                    <PubDate>
                        <Year>1984</Year>
                        <Month>May</Month>
                        <Day>12</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Medicina clnica</Title>
                <ISOAbbreviation>Med Clin (Barc)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Hemolytic-uremic syndrome caused by estrogen-progestagen combined oral contraceptives].</ArticleTitle>
            <Pagination>
                <MedlinePgn>824</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Otero Gonzlez</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Santos</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jimnez</LastName>
                    <ForeName>J L</ForeName>
                    <Initials>JL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gil</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Snchez-Guisande</LastName>
                    <ForeName>D</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Temes Montes</LastName>
                    <ForeName>X L</ForeName>
                    <Initials>XL</Initials>
                </Author>
            </AuthorList>
            <Language>spa</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016422">Letter</PublicationType>
            </PublicationTypeList>
            <VernacularTitle>Sndrome hemoltico urmico por anticonceptivos orales compuestos por estrgenos-progestgenos.</VernacularTitle>
        </Article>
        <MedlineJournalInfo>
            <Country>SPAIN</Country>
            <MedlineTA>Med Clin (Barc)</MedlineTA>
            <NlmUniqueID>0376377</NlmUniqueID>
            <ISSNLinking>0025-7753</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D003276">Contraceptives, Oral</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D003277">Contraceptives, Oral, Combined</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>3J8Q1747Z2</RegistryNumber>
                <NameOfSubstance UI="D009644">Norgestrel</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>423D2T571U</RegistryNumber>
                <NameOfSubstance UI="D004997">Ethinyl Estradiol</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>5W7SIA7YZW</RegistryNumber>
                <NameOfSubstance UI="D016912">Levonorgestrel</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003276">Contraceptives, Oral</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003277">Contraceptives, Oral, Combined</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004997">Ethinyl Estradiol</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006463">Hemolytic-Uremic Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016912">Levonorgestrel</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009644">Norgestrel</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1984</Year>
                <Month>5</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1984</Year>
                <Month>5</Month>
                <Day>12</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1984</Year>
                <Month>5</Month>
                <Day>12</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6429463</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">6130055</PMID>
        <DateCreated>
            <Year>1983</Year>
            <Month>03</Month>
            <Day>11</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1983</Year>
            <Month>03</Month>
            <Day>11</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>05</Month>
            <Day>30</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <JournalIssue CitedMedium="Print">
                    <Volume>162</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>1982</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>IMJ. Illinois medical journal</Title>
                <ISOAbbreviation>IMJ Ill Med J</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Phenylbutazone associated glomerulonephritis. Glomerulonephritis and fever.</ArticleTitle>
            <Pagination>
                <MedlinePgn>471-2</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Rothschild</LastName>
                    <ForeName>B M</ForeName>
                    <Initials>BM</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>IMJ Ill Med J</MedlineTA>
            <NlmUniqueID>7703940</NlmUniqueID>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>GN5P7K3T8S</RegistryNumber>
                <NameOfSubstance UI="D010653">Phenylbutazone</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002062">Bursitis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005335">Fever of Unknown Origin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005921">Glomerulonephritis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010653">Phenylbutazone</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1982</Year>
                <Month>12</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1982</Year>
                <Month>12</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1982</Year>
                <Month>12</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6130055</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">8648930</PMID>
        <DateCreated>
            <Year>1996</Year>
            <Month>07</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1996</Year>
            <Month>07</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0085-2538</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>49</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>1996</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Kidney international</Title>
                <ISOAbbreviation>Kidney Int.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Gene expression of hepatic cholesterol 7 alpha-hydroxylase in the course of puromycin-induced nephrosis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>855-60</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Cholesterol conversion to and biliary excretion of bile acids represents the principal pathway of cholesterol catabolism in mammals. Cholesterol 7 alpha-hydroxylase (Ch-7 alpha-H) is the first and the rate limiting step in bile acid production. Recently, Ch-7 alpha-H enzymatic activity has been shown to be normal in rats with established puromycin aminonucleoside-induced nephrosis (NS). To our knowledge, the gene expression of Ch-7 alpha-H in NS has not been investigated. We measured hepatic Ch-7 alpha-H mRNA and protein (by Northern and Western blot analyses) in rats at baseline and longitudinally during the course of induction and chronic phase of puromycin (PAN) induced NS. Groups of placebo-treated (controls) and diet-induced hypercholesterolemic (DHC) rats were included for comparison. The NS and DHC animals exhibited severe hypercholesterolemia of similar magnitude. Hepatic Ch-7 alpha-H transcript and protein remained virtually unchanged throughout the study period in the NS group. In contrast, Ch-7 alpha-H gene expression was markedly up-regulated in the DHC group. These observations suggest that hepatic Ch-7 alpha-H gene expression may be inappropriately low for the degree of the associated hypercholesterolemia in the NS group. It should be noted, however, that hepatic tissue cholesterol concentration was normal in the NS group and greatly increased in the DHC group. This can account for the disparity in Ch-7 alpha-H mRNA levels between the two groups since intracellular rather than extracellular cholesterol modulates Ch-7 alpha-H gene expression. In conclusion, the present study revealed that hepatic Ch-7 alpha-H gene expression remains unchanged during the course of PAN-induced NS in rats. It thus appears that generation and maintenance of hypercholesterolemia in this model of NS does not involve significant alteration of Ch-7 alpha-H gene expression.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Liang</LastName>
                    <ForeName>K H</ForeName>
                    <Initials>KH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, University of California, Irvine, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Oveisi</LastName>
                    <ForeName>F</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vaziri</LastName>
                    <ForeName>N D</ForeName>
                    <Initials>ND</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Kidney Int</MedlineTA>
            <NlmUniqueID>0323470</NlmUniqueID>
            <ISSNLinking>0085-2538</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012709">Serum Albumin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>4A6ZS6Q2CL</RegistryNumber>
                <NameOfSubstance UI="D011691">Puromycin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.13.17</RegistryNumber>
                <NameOfSubstance UI="D002790">Cholesterol 7-alpha-Hydroxylase</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002790">Cholesterol 7-alpha-Hydroxylase</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004032">Diet</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015870">Gene Expression</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006937">Hypercholesterolemia</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009401">Nephrosis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011507">Proteinuria</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011691">Puromycin</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017207">Rats, Sprague-Dawley</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012709">Serum Albumin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1996</Year>
                <Month>3</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1996</Year>
                <Month>3</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1996</Year>
                <Month>3</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8648930</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
